document incorporate reference portion proxy statement file april iii explanatory note amendment bristolmyers squibb company annual report year end december include restate consolidated financial statement december year period end december company experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler incentive generally offer end quarter order incentivize wholesaler purchase product sufficient meet company quarterly sale projection establish company senior management april company disclose substantial buildup develop subsequently undertake plan work orderly fashion wholesaler inventory level late october base review consideration previously disclose buildup wholesaler inventory company pharmaceutical business incentive offer certain wholesaler advice company independent auditor pricewaterhousecooper llp companydetermine required restate sale earning correct error time revenue recognition certain sale certain pharmaceuticals wholesaler time company undertake analysis transaction incentive practice pharmaceuticals wholesaler company determine certain incentivize transaction certain wholesaler account consignment model recognize revenue transaction shipment determination involve evaluation variety criterion number complex accounting judgment result analysis company determine certain sale large wholesaler pharmaceutical business account consignment model base relationship incentive offer wholesaler inventory hold wholesaler follow determination restate sale earning matter describe company determine correct certain historical accounting policy conform account generally accept accounting principle gaap certain know error application gaap previously record case company believe error material company consolidated financial statement addition restatement process company investigate accounting practice certain area involve significant judgment determine restate additional item respect company conclude error application gaap include certain revision inappropriate account senior management set aggressive target company business error inappropriate accounting correct restatement arise period unrealistic expectation consequent overestimation anticipate performance certain company product program result forego company restate financial statement year end december include correspond interim period quarterly period end march june restatement affect period prior impact restatement prior period reflect adjustment opening retain earning january connection audits restatement previously issue financial statement company consolidated financial statement year end december company independent auditor pricewaterhousecooper llp identify communicate company audit committee material weakness define standard establish american institute certify public accountant relate company accounting public financial report significant matter initial recording management review oversight certain accounting matter year company search hire new chief financial officer outside company restaffe controller position create position chief compliance officer change leadership pharmaceutical group response wholesaler inventory buildup matter identify restatement adjustment direction audit committee year senior management direct company dedicate resource step strengthen control process procedure order identify rectify past accounting error prevent recurrence circumstance result need restate prior period financial statement company revise budgeting process emphasize bottomup approach contrast topdown approach company implement review certification process annual quarterly report security exchange act amend process design enhance monitor wholesaler inventory addition company process expand business risk disclosure group include senior management include chief executive officer chief financial officer take number additional step design create open environment communication flow information company company continue identify implement action improve effectiveness disclosure control procedure internal control include plan enhance resource training respect financial reporting disclosure responsibility review action audit committee independent auditor restatement previously issue financial statement reduce company net earning dilute earning share year end december approximately million million million respectively increase company net earning dilute earning share month end june approximately million company accounting consignment model certain sale large wholesaler pharmaceuticals business discuss item management discussion analysis financial condition result operation ii note restatement previously issue financial statement restate consolidated financial statement disclose nature restatement adjustment show impact category restatement adjustment net sale earning continue operation minority interest income taxis earning continue operation discontinue operation net earning relate share amount restate annual period cumulative impact adjustment condense statement operation condense balance sheet restate annual period addition note restate consolidated financial statement show effect adjustment opening retain earning january adjustment reflect impact restatement period prior information impact restatement year reference item select financial datum ii discussion company revenue recognition policy reference note accounting policy restate consolidated financial statement company revise note restate consolidated financial statement present revise accounting policy certain matter include restatement note consolidated financial statement affect restatement revise amend restate item item ii item iv original information include original amend explanatory caption begin item set forth nature revision item company amend annual report quarterly report form q period affect restatement end prior december financial statement relate financial information contain report long rely discussion event development subsequent december company quarterly report form q quarterly period end september file concurrently company subsequent filing item businessthis item revise reflect restatement company business segment reorganization effective quarter certain development occur subsequent filing original respect company business include update information respect patent own license company addition item revise incorporate certain conform change description bristolmyer squibb company general bristolmyers squibb company bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger company division subsidiarie major producer distributor pharmaceuticals healthcare relate product reportable segmentspharmaceutical nutritional healthcare company announce plan divestiture clairol zimmer business accordingly operation business reflect discontinued operation accompany restate consolidated financial statement november company complete sale clairol billion august company spin zimmer holdings inc taxfree distribution october company acquire dupont pharmaceutical business dupont ei du pont de nemour company billion cash dupont primarily domestic pharmaceutical imaging product business focus research development addition november company purchase million share imclone system incorporate imclone share million represent share outstanding prior company commencement public tender offer imclone share equity investment imclone strategic agreement company imclone include arrangement subject additional payment company codevelop copromote investigational cancer drug erbitux transaction finance proceed issuance billion commercial paper issuance billion mediumterm note internal cash flow business segment reference note segment information restate consolidated financial statement company reportable segmentspharmaceutical nutritional healthcare pharmaceutical segment pharmaceutical segment manufacture distribute sell brand generic ethical pharmaceutical product sell worldwide primarily wholesaler retail pharmacy hospital medical profession company manufacture product puerto rico foreign country pharmaceutical sale account approximately company restate sale respectively sale select product product category pharmaceutical segment follows restate restate restate dollar million pravachol glucophage oncology therapeutic network plavix taxol paraplatin zerit avapro monopril serzone cefzil buspar capotencapozide glucovance tequin videx glucophage xr pravachol pravastatin sodium hmg coa reductase inhibitor indicate primary hypercholesterolemia compositon matter patent expire october patent expire expire internationally glucophage glucophage metformin oral antidiabete agent type noninsulindependent diabete hatch xr glucovance waxman exclusivity expire glucophage september generic metformin available january hatchwaxman data protection expire glucophage xr october glucovance july oncology therapeutic network specialty distributor anticancer medicine relate product company otn enter agreement mckesson corporation distribution pharmaceutical product relate otn company restate previously issue financial statement account sale agreement consignment model describe fully note restatement previously issue financial statement restate consolidated financial statementsplavix clopidogrel platelet inhibitor codevelope jointly market sanofisynthelabo composition matter patent expire july november internationally discussion relate litigation reference item legal proceeding note litigation matter restate consolidated financial statement taxol paclitaxel treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment aidsrelated kaposi sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment node positive breast cancer treatment nonsmall cell lung carcinoma cisplatin data exclusivity taxol japan expire july european union september patent cover aspect taxol extend japan europe discussion relate litigation reference item legal proceeding note litigation matter restate consolidated financial statement paraplatin carboplatin chemotherapeutic agent treatment ovarian cancer patent expire france june expire april zerit stavudine treatment person advance human immunodeficiency virus hiv infection patent expire june internationally avapro irbesartan angiotensin ii receptor antagonist indicate treatment hypertension codevelope jointly market sanofisynthelabo composition matter patent expire september internationally monopril fosinopril sodium secondgeneration angiotensin convert enzyme ace inhibitor onceaday dosing indicate treatment hypertension composition matter patent expire december extend month pediatric extension expect expire june composition matter patent expire expire internationally serzone nefazodone antidepressant treatment patent expire march extend month pediatric extension expect expire september patent expire expire internationally cefzil cefprozil oral cephalosporin treatment respiratory infection sinusitis patent expire december internationally buspar buspirone novel antianxiety agent persistent anxiety accompany depressive symptom anxiolytic use patent expire food drug administration fda grant company additional month exclusivity base performance pediatric study patent outside expire discussion relate litigation reference item legal proceeding note litigation matter restate consolidated financial statement capotencapozide captopril ace inhibitor patent expire significant international market tequin gatifloxacin advanced quinolone antiinfective patent expire december expect patent term extension expire expire internationally january june videxvidex ec didanosine antiretroviral drug treatment adult pediatric patient advance hiv infection method use patent expire august internationally patent hold national institutes health company license patent nonexclusive october nutritional segment nutritional segment manufacture distribute sell infant formula nutritional product product generally sell wholesaler retailer promote primarily consumer worldwide advertising company manufacture product puerto rico foreign country nutritional sale account company restate sale respectively sale select product product category nutritional segment follows restate restate restate dollar million enfamil enfalac nutramigen prosobee child nutritional supplement healthcare segment healthcare segment consist convatec medical imaging consumer medicine japan healthcare sale account company restate sale company restate sale convatecconvatec manufacture distribute sell ostomy modern wound skin care product principal brand convatec include surfit esteem aquacel duoderm product market sell worldwide primarily hospital medical profession company manufacture product united kingdom convatec sale account approximately company sale case restate medical imaging medical imaging manufacture distribute sell cardiovascular imaging product principal brand medical imaging include cardiolite definity product market sell worldwide primarily hospital medical profession company manufacture product puerto rico medical imaging purchase dupont acquisition complete october generate sale million fourth quarter consumer medicine consumer medicine manufacture distribute sell overthecounter health care product principal consumer health care brand include excedrin bufferin comtrex product generally sell retailer promote primarily consumer japan advertising product manufacture puerto rico japan consumer medicine sale account company restate sale source availability raw material general bristolmyer squibb purchase principal raw material supply open market substantially material obtainable number source loss source supply material adverse effect company patent trademark license company own license number patent united states foreign country cover product develop brand name trademark product company consider overall protection patent trademark license right material value act protect right infringement composition matter patent monopril expire december extend month pediatric extension expect expire june composition matter patent serzone expire march extend month pediatric extension expect expire september additional patent expect expire year include patent cefzil december composition matter patent plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july videx ec october note expiry date extend additional month pediatric extension completion acceptance pediatric study fda advance expiration competition distribution customer market bristolmyer squibb compete generally broadbase highly competitive principal mean competition market product bristolmyer squibb include quality service price product performance pharmaceutical product product convatec promote national international basis medical journal directly medical profession company directtoconsumer advertising number pharmaceutical product product bristolmyer squibb generally advertise promote national international basis use television radio print medium consumer offer window instore display bristolmyer squibb product principally sell wholesale retail trade nationally internationally certain product sell drug manufacturer hospital medical profession sale amerisourcebergen corporation cardinal health inc cardinal mckesson corporation mckesson account company net sale restate sale cardinal account company net sale restate sale mckesson account company net sale restate company account certain sale pharmaceutical product cardinal mckesson consignment model discussion company accounting consignment model relationship wholesaler note accounting policy note restatement previously issue financial statement restate consolidated financial statement item management discussion analysis financial condition result operation ii research development research development essential bristolmyer squibb business pharmaceutical research development carry bristolmyers squibb pharmaceutical research institute major facilities princeton hopewell new brunswick new jersey wilmington delaware wallingford connecticut pharmaceutical research development carry facility united states belgium canada france italy united kingdom management continue emphasize leadership innovation productivity strategy success pharmaceutical research institute bristolmyers squibb spend million million million company sponsor research development activity pharmaceutical research development spending percentage restate pharmaceutical sale compare research development spending fourth quarter relate dupont imclone million regulation aspect company business subject degree government regulation country operation conduct company policy comply fully regulatory requirement apply product operation product country government regulation significant general trend stringent regulation company devote significant time effort expense address extensive governmental regulatory requirement applicable business governmental regulatory action result recall seizure product suspension revocation authority necessary production sale product civil criminal sanctionsin united states drug medical device diagnostic food industry company operate long subject regulation federal state local agency primarily product manufacture safety efficacy advertising labeling addition governmental body united states country express concern cost relate health care case focus attention pricing drug appropriate drug utilization government regulation area exist country expand significantly united states country future company unable predict extent business affect future regulatory development believe substantial experience deal governmental regulatory requirement restriction operation world development new improved product enable compete effectively environment employee bristolmyer squibb employee continue operation approximately people december domestic foreign operation reference note financial instrument note segment information restate consolidated financial statement international operation subject certain risk inherent conduct business abroad include possible nationalization expropriation price exchange control limitation foreign participation local enterprise restrictive governmental action addition change relative value currency place time time effect favorable unfavorable bristolmyer squibb operation currency restriction relate repatriation earning certain country indicate brand name product register trademark own company erbitux trademark imclone system incorporate avapro plavix trademark sanofisynthelabo france corp corzide delestrogen corgard florinef trademark king pharmaceuticals inc estrace trademark galen chemicals limited viactiv trademark mcneilppc inc glucophage glucophage xr glucovance trademark merck sante sas associate merck kgaa darmstadt germany license bristolmyers squibb company solage trademark galderma sa ovcon trademark warner chilcott inc sea breeze trademark shiseido company ltd abilify trademark otsuka pharmaceutical company ltd item legal proceeding item update event development occur subsequent filing original addition item revise incorporate certain conforming change lawsuit claim proceeding pende company certain subsidiary significant describe taxol litigation company file lawsuit assert number generic drug company infringe patent cover method administer paclitaxel file abbreviate new drug application seek regulatory approval sell paclitaxel action consolidate discovery district court district new jersey district court company assert monetary claim defendant seek prevent defendant marketing paclitaxel manner violate patent defendant assert infringe company patent patent invalid unenforceable early district court invalidate claim company patent issue april court appeal federal circuit affirm district court summary judgment invalidity claim patent issue claim relate lowdose threehour administration paclitaxel patient give specify regimen premedicants administration paclitaxel appellate court remand claim district court proceeding company file additional patent infringement suit company seek market generic paclitaxel september defendant receive final approval food drug administration fda abbreviate new drug application paclitaxel marketing product fda announce additional final approval sale additional generic product begin defendant assert counterclaim seek damage allege antitrust unfair competition violation company believe patent valid file suit counterclaim assert believe merit lawsuit defendant assert counterclaim settle defendant agree drop claim relate paclitaxel company grant license certain paclitaxel patent right file initial patent infringement suit private action file party allege antitrust consumer protection similar claim relate company action obtain enforce patent right plaintiff seek declaratory judgment damage include treble andor punitive damage allow disgorgement injunctive relief june group state attorney general district columbia puerto rico virgin islands bring similar claim september federal trade commission ftc initiate investigation relate paclitaxel january company announce reach agreement principle settle substantially antitrust litigation surround taxol taxol antitrust settlement expect million accrue quarter certain important term condition settlement remain finalized certain settlement require court approval final approval state attorney general taxol litigation contingent agreement relate term injunctive relief provision remain negotiate term incorporate certain claimant include number health insurer exist settlement framework company discussion number insurer ultimately join propose settlement predict certainty time company reach agreement ftc staff term consent order resolve ftc investigation propose consent order subject review approval ftc commissioner respect abovementione propose settlement possible time reasonably assess final outcome lawsuit orreasonably estimate possible loss range loss respect lawsuit propose settlement final resolve taxolrelate antitrust consumer protection similar claim company prevail final nonappealable determination ensue litigation impact material buspar litigation november company obtain patent patent patent relate method buspar buspirone company timely submit information relate patent fda list fda publication commonly know orange book fda list patent orange book delist patent suit genericdrug manufacturer sue fda company compel delist patent orange book district court decline order delist patent order company cause delist patent orange book company comply court order appeal decision united states court appeal federal circuit appellate court reverse district court order delist concurrently company seek enforce patent action generic drug manufacturer antitrust suit follow delist patent orange book number purchaser buspirone generic drug maker file lawsuit company allege improperly trigger statutory marketing exclusivity plaintiff claim violation antitrust consumer protection similar law attorney general states puerto rico file suit company parallel allegation plaintiff amend allegation include charge agreement company generic company improperly block entry generic buspirone market plaintiff seek declaratory judgment damage include treble andor punitive damage allow disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl grant company motion patent antitrust case consolidate single forum court buspirone litigation pende issue opinion date february opinion court find patent cover use buspirone infringe second opinion court deny company motion dismiss federal antitrust state law claim second opinion allow claim company proceed federal antitrust claim damage accrue year file complaint government investigation ftc number state attorney general initiate investigation concern matter allege antitrust suit discuss company cooperate investigation number attorney general file action company note propose settlement january company announce reach agreement principle settle substantially antitrust litigation surround buspar buspar settlement expect million million accrue fourth quarter million accrue quarter million accrue quarter write settlement agreement number party sign certain settlement require court approval number health insurer agree propose settlement framework case ultimately settle predict certainty time company reach agreement ftc staff term consent order resolve ftc investigation propose consent order subject review approval ftc commissioner respect abovementione propose settlement buspar antitrust litigation possible time reasonably assess final outcome lawsuit reasonably estimate possible loss range loss respect lawsuit propose settlement final resolve busparrelate antitrust consumer protection similar claim company prevail final nonappealable determination ensue litigation impact material vanlev litigation april june company chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd name defendant number class action lawsuit allege violation federal security law regulation action consolidate action district court district new jersey plaintiff claim defendant disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability product vanlev period november april plaintiff submit amend complaint add allegation company present chairman board chief executive officer peter r dolan chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability vanlev period april march number relate class action make essentially allegation file district court southern district new york action transfer district court district new jersey plaintiff purport seek compensatory damage cost expense behalf shareholder possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determination litigation impact material plavix litigation company owner entity plaintiff pende patent infringement lawsuit united states district court southern district new york entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v dr reddy laboratories ltd dr reddy laboratories inc cv rws suit base patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix patent disclose claim thing use clopidogrel prevent secondary ischemic event plaintiff infringement position base defendant filing abbreviate new drug application fda seek approval sell generic clopidogrel prior expiration patent suit possible time reasonably assess final outcome lawsuit reasonably estimate possible loss range loss respect lawsuit patent protection plavix lose impact company operation material security mattersduring period march company number current officer name defendant number security class action lawsuit allege violation federal security law regulation plaintiff variously allege defendant disseminate materially false misleading statement fail disclose material information concern different matter safety efficacy commercial viability vanlev discuss company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone system incorporate imclone imclone product erbitux discuss allegation concern vanlev transfer district court district new jersey consolidated action pende remain action consolidate pende district court southern district new york allegation remaining action cover period january april plaintiff seek compensatory damage cost expense october number company officer director director name defendant shareholder derivative suit pende district court southern district new york company nominal defendant suit allege thing violation federal security law breach contract fiduciary duty connection company sale incentive certain wholesaler inventory level wholesaler investment imclone imclone product erbitux similar action pende new york state court plaintiff seek damage cost attorney fee april sec initiate inquiry wholesaler inventory issue reference formal investigation august december investigation expand include certain accounting issue include issue relate establishment reserve account certain asset sale october united states attorney office district new jersey announce investigation wholesaler inventory issue reference expand cover subject matter sec investigation opinion management material adjustment necessary correct previously issue financial statement record restatement company expect restatement describe company reasonably assess final outcome investigation time company cooperate investigation possible time reasonably assess final outcome litigation investigation reasonably estimate possible loss range loss respect litigation investigation company produce document actively cooperate investigation investigation result assertion criminal andor civil claim company prevail final nonappealable determination litigation investigation impact material erisa litigation december quarter company name defendant number class action bring federal employee retirement income security act erisa case pende district court southern district new york district new jersey plaintiffs allege defendant breach fiduciary duty impose erisa owe participant bristolmyers squibb company saving investment program program include duty disseminate material information concern safety datum company product vanlev company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux connection allegation plaintiff assert defendant breach fiduciary duty diversify program asset monitor investment alternative avoid conflict interest remedy allege fiduciary breach cofiduciarie case pende district new jersey plaintiffs additionally allege violation defendant duty disseminate material information concern alleged anticompetitive activity relate company product buspar taxol pravachol plaintiff seek recover loss cause defendant allege violation erisa attorney fee possible time reasonably assess final outcome matter reasonably estimate possible loss range loss respect lawsuit company prevail final nonappealable determination matter impact material average wholesale pricing litigation company number pharmaceutical manufacturer defendant series state federal action private plaintiff bring purport class action complaint file attorney general state county allege manufacturer reporting price certain product result false overstated average wholesale price awp turn improperly inflate reimbursement pay medicare beneficiary insurer state medicaid programs medical plan health care provider prescribe administer product federal case state case include attorney general case remove federal court consolidate pretrial purpose transfer united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september private plaintiff awp multidistrict litigation file master consolidated complaint master complaint supersede complaint preconsolidate constituent case master complaint assert claim federal rico statute state consumer protection fair trade statute company defendant move dismiss master complaint motion hear january nevada montana attorney general move respective case remand state court argument motion schedule march company defendant related state court proceeding new york new jersey california arizona tennessee federal court proceeding new york commence county suffolk new york new jersey state court proceeding currently stay company defendant remove intend remove state court case federal court seek transfer awp multidistrict litigation company anticipate county suffolk case transfer plaintiff seek damage injunctive relief aim manufacturer price reporting practice case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing marketing practice drug cover medicare andor medicaid requests record come united states attorney office district massachusetts office inspector general department health human service conjunction civil division department justice state company produce document actively cooperate investigation result assertion criminal andor civil claim company unable assess outcome reasonably estimate possible loss range loss respect investigation include imposition fine penalty administrative remedy breast implant litigationthe company subsidiary medical engineering corporation mec certain company remain defendant number claim lawsuit allege damage personal injury type result polyurethanecovered breast implant smoothwalle breast implant manufacture mec relate company vast majority claim company direct lawsuit resolve settlement trial likewise claim potential claim company register nationwide class action settlement approve federal district court birmingham alabama revise settlement resolve revise settlement company establish accrual respect breast implant product liability litigation company believe possible loss addition amount accrue material item select financial datum fiveyear financial summary set forth item revise reflect restatement fiveyear financial summary restate restate restate restate restate million share datum income statement datum net sale expense cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure item earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation earning continue operation common share basic dilute dividend declare common share financial position datum december total asset longterm debt stockholder equity average common share outstanding basic average common share outstanding dilute include gain sale businessesproduct line tax million million million million include charge prescription drug pricing litigation million pende future product liability claim million taxis include minority interest expense income unconsolidate affiliate financial position datum relate company asset liability include discontinued operation year restatement adjustment affect year set forth follow table previously previously report restate report restate dollar million net sale earning continue operation earning continue operation common share basic diluted financial position datum december total asset stockholder equity restatement adjustment affect year adjustment respect sale return sale rebate accrual capitalize research development payment acquisition divestiture liabilitie income taxis restatement item describe note restatement previously issue financial statement restate consolidated financial statement certain adjustment stockholder equity affecting period prior january include adjustment dividend accrual reflect adjustment opening retain earning january restate year information note restatement previously issue financial statement note discontinued operation note acquisition divestiture note restructure item note alliance investment note litigation matter restate consolidated financial statement item management discussion analysis financial condition result operation management discussion analysis financial condition result operation set forth item revise reflect restatement company business segment reorganization effective quarter certain event occur subsequent filing original incorporate certain conform change addition company update disclosure respect recently issue accounting standard critical accounting policy contractual obligation retirement benefit recent development company experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler incentive generally offer end quarter order incentivize wholesaler purchase product sufficient meet company quarterly sale projection establish company senior management april company disclose substantial buildup develop subsequently undertake plan work orderly fashion wholesaler inventory level late october base review consideration previously disclose buildup wholesaler inventory company pharmaceutical business incentive offer certain wholesaler advice company independent auditor pricewaterhousecooper llp company determine require restate sale earning correct error time revenue recognition certain sale certain pharmaceuticals wholesaler time company undertake analysis transaction incentive practice pharmaceuticals wholesaler company determine certain incentivize transaction certain wholesaler account consignment model recognize revenue transaction shipment determination involve evaluation variety criterion number complex accounting judgment result analysis company determine certain sale large wholesaler pharmaceutical business account consignment model base relationship incentive offer wholesaler inventory hold wholesaler follow determination restate sale earning matter describe company determine correct certain historical accounting policy conform account generally accept accounting principle gaap certain know error application gaap previously record case company believe error material company consolidated financial statement addition restatement process company investigate accounting practice certain area involve significant judgment determine restate additional item respect company conclude error application gaap include certain revision inappropriate accounting description restatement adjustment impact adjustment company previously issue financial statement note restatement previously issue financial statement restate consolidated financial statement senior management set aggressive target company business error inappropriate accounting correct restatement arise period unrealistic expectation consequent overestimation anticipate performance certain company product program result forego company restate financial statement year end december include correspond interim period quarterly period end march june restatement affect period prior impact restatement prior period reflect adjustment opening retain earning january connection audits restatement previously issue financial statement company consolidated financial statement year end december company independent auditor pricewaterhousecooper llp identify communicate company audit committee material weakness define standard establish american institute certify public accountant relate company accounting public financial report significant matter initial recording management review oversight certain accounting matter year company search hire new chief financial officer outside company restaffe controller position create position chief compliance officer change leadership pharmaceutical group response wholesaler inventory buildup matter identify restatement adjustment direction audit committee year senior management direct company dedicate resource step strengthen control process procedure order identify rectify past accounting error prevent recurrence circumstance result need restate prior period financial statement company revise budgeting process emphasize bottomup approach contrast topdown approach company implement review certification process annual quarterly report security exchange act amend process design enhance monitor wholesaler inventory addition company process expand business risk disclosure group include senior managementinclude chief executive officer chief financial officer take number additional step design create open environment communication flow information company company continue identify implement action improve effectiveness disclosure control procedure internal control include plan enhance resource training respect financial reporting disclosure responsibility review action audit committee independent auditor company account certain sale large wholesaler pharmaceutical business consignment model discuss net sale note restatement previously issue financial statement restate consolidated financial statement follow management discussion analysis financial condition result operation reference amount reflect balance amount restate basis summary consistent company strategy focused pharmaceutical company number transaction complete include divestiture nonpharmaceutical business clairol beauty care zimmer orthopaedic result business report discontinued operation exclude consolidated sale expense year present addition fourth quarter company acquire dupont pharmaceutical business dupont equity investment imclone system incorporate imclone biotechnology company bristolmyer squibb report billion annual restate global sale increase domestic restate sale represent worldwide restate sale increase billion international sale increase foreign exchange unfavorable impact billion sale company include sale dupont acquisition million date acquisition company important product line significant contribution company sale growth experience double digit growth restate worldwide basis year company blockbuster product annual restate sale excess billionpravachol glucophage plavix taxol paclitaxel fact pravachol annual restate sale excess billion addition product company product line million annual sale include million annual sale million annual sale case restate information pharmaceutical prescriber demand reference table compare change net sale restate basis estimate total retail mail order customer prescription growth certain company primary care pharmaceutical product earning continue operation minority interest income taxis restate decrease billion billion net earning continue operation restate decrease billion billion basic diluted earning share continue operation restate decrease respectively respectively decline earning company largely billion pretax charge writeoff inprocess research development connection dupont imclone transaction net earning total company continue discontinue operation restate increase billion billion total company basic diluted earning share restate increase respectively respectively increase total company earning drive billion aftertax gain restate sale clairol bristolmyer squibb financial position remain strong december company hold billion cash time deposit marketable security approximately billion cash time deposit marketable security hold company foreign subsidiary repatriation cash likely require additional tax provision reflect restate consolidated financial statement discussion matter critical accounting policiesincome taxis cash provide operating activity reach billion restate connection dupont imclone transaction company issue billion note billion mature billion mature bear coupon interest rate respectively return shareholder include dividend distribution billion stock repurchase billion dividend declare common share increase share pay dividend declare common share consistent company mission extend enhance human life develop highestquality product company invest billion restate research development increase restate research development spending include million relate dupont imclone research development dedicated pharmaceutical product increase compound annualize growth spending past year continue investment lead discovery innovative new product development new indication exist product lead regulatory filing include vanlev hypertension aripiprazole schizophrenia plavix acute coronary syndrome addition company receive seven regulatory approval supplemental submission include tequin shortcourse fiveday regimen composition matter patent monopril expire december extend month pediatric extension expect expire june composition matter patent serzone expire march extend month pediatric extension expect expire september additional patent expect expire year include patent cefzil december composition matter patent plavix july addition use patent paraplatin expire april hatchwaxman data protection expire glucophage xr october glucovance july videx ec october expiry date extend additional month pediatric extension completion acceptance pediatric study food drug administration fda advance expiration october company acquire dupont pharmaceutical business e du pont de nemour company billion company announce collaboration agreement exelixis inc create new generation cancer drug selectively destroy cancer harbor defect tumor suppress gene pathway september company enter commercial agreement imclone codevelop copromote investigational cancer drug erbitux commercial agreement company require pay imclone aggregate billion achievement milestone million pay million payment charge earning remain million record equity investment november company purchase million share imclone share million represent approximately imclone share outstanding prior commencement public tender offeron december imclone announce fda refuse accept filing biologic license application bla submit imclone erbitux bla submit gain marketing approval treat irinotecanrefractory colorectal carcinoma january subcommittee oversight investigation house energy commerce committee announce investigate question conduct imclone development erbitux january imclone announce receive informal inquiry security exchange commission inquiry department justice aforementione subcommittee company cooperate investigation march agreement imclone revise reduce total payment million billion revise agreement company agree pay imclone million march million march aggregate million achievement milestone revise agreement company agree pay imclone distribution fee base flat rate product revenue north america discussion company accounting equity investment imclone payment revise agreement imclone note alliance investment restate consolidated financial statement describe note restatement previously issue financial statement unaudite consolidated financial statement include company quarterly report form q quarterly period end september file concurrently company determine million payable march recognize march accordingly company correct error restate quarter acquire inprocess research development charge expense million million payment record remainder payment additional equity investment eliminate income statement effect portion payment company economic claim equity investment imclone carrying value company approximately equity investment imclone million december pershare basis carry value company imclone investment closing market value imclone share december respectively quarter company record pretax charge earning million temporary decline market value imclone fair value equity investment imclone determine charge base market value imclone share september net sale sale restate increase billion include sale million relate dupont acquisition complete october domestic sale restate increase international sale increase foreign exchange unfavorably impact sale decrease foreign exchange unfavorably impact sale sale growth result increase volume increase change sell price decrease foreign exchange rate fluctuation sale increase billion increase reflect increase volume increase change sell price decrease foreign exchange rate fluctuation sale increase billion result increase volume increase change sell price decrease foreign exchange rate fluctuation general business company seasonal information pharmaceutical prescriber demand reference table compare change net sale restate basis estimate total retail mail order customer prescription growth certain company primary care pharmaceutical product significant portion company sale wholesaler company experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler include discount buyin anticipation price increase extend payment term certain pharmaceuticals wholesaler incentive generally offer end quarter order incentivize wholesaler purchase product sufficient meet company quarterly sale projection establish company senior management timing company recognition revenue sale wholesaler differ wholesaler period historically company recognize revenue sale shipment product customer gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net discount rebate estimate sale allowance accrual return consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis additional discussion company revenue recognition policy note accounting policy restate consolidated financial statement company restate previously issue financial statement correct timing revenue recognition certain previously recognize pharmaceutical sale cardinal health inc cardinal mckesson corporation mckesson large wholesaler company pharmaceuticals business base application criterion describe record error time shipment account consignment model company determine shipment product cardinal shipment product mckesson meet consignment model criterion set forth july july respectively case continue end period accordingly consignment model require apply shipment prior respective period company recognize revenue respect sale cardinal mckesson shipment product company generally view approximately month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average apply consignment model sale cardinal mckesson company define inventory excess wholesaler ordinary course business inventory level inventory week week supply respectively base level inventory cardinal mckesson require basis negotiation incentive grant additional discussion application consignment model sale cardinal mckesson note restatement previouslyissue financial statement restate consolidated financial statement result restatement adjustment net sale reduce million million million respectively correspond reduction earning continue operation minority interest income tax million million million respectively separately discussion march company enter distribution agreement mckesson provision warehousing order fulfillment service company oncology therapeutic network otn specialty distributor anticancer medicine relate product prior restatement company record error sale agreement shipment product mckesson company restate previously issue financial statement account sale consignment model describe fully note restatement previously issue financial statement restate consolidated financial statement result reduction net sale earning continue operation minority interest income taxis million million respectively december company aggregate cost pharmaceutical product hold cardinal respect mckesson account consignment model accordingly reflect consignment inventory company consolidated balance sheet approximately million million million respectively approximately million december relate otn defer revenue record gross invoice sale price relate inventory pharmaceutical product account consignment model approximately million million million december respectively approximately million december relate otn result restatement application consignment model approximately million sale calculate net customary early pay cash discount reverse period approximately million expect recognize approximately million project recognize sale cardinal mckesson represent approximately pharmaceutical net sale respectively restate basis company determine sale incentive offer wholesaler buildup inventory wholesaler consignment model criterion discuss meet accordingly company recognize revenue product ship wholesaler company estimate inventory pharmaceutical product hold pharmaceuticals wholesaler excess approximately month supply case company exclusive product approximately half month supply case plavix avapro market company alliance sanofisynthelabo approximately month supply case company nonexclusive product range approximately million million december company estimate base project prescription demandbase sale product company analysis thirdparty information include information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum company internal information company estimate subject inherent limitation estimate rely thirdparty datum certain thirdparty information form estimate reflect limitation april company disclose substantial buildup wholesaler inventory pharmaceutical business develop subsequently undertake plan work orderly fashion wholesaler inventory level facilitate orderly workdown company plan include continue offer sale incentive reduce level certain wholesaler respect mckesson cardinal company enter agreement orderly workdown provide wholesaler specify level purchase company offer specify level incentive workdown period company expect orderly workdown inventory pharmaceutical product hold pharmaceutical wholesaler substantially complete end company expect consignment model criterion long meet respect company pharmaceutical sale cardinal mckesson abovementione sale relate otn end december company aggregate cost pharmaceutical product hold cardinal mckesson account consignment model accordingly reflect consignment inventory company consolidated balance sheet approximately million december defer revenue record gross invoice sale price relate inventory approximately million include approximately million related otn company estimate base datum note inventory pharmaceutical product hold pharmaceuticals wholesaler excess approximately month supply case company exclusive product approximately half month supply case plavix avapro market company alliance sanofisynthelabo approximately month supply case company non exclusive product range approximately million level supply million excess level supply december estimate subject inherent limitation note company expect account certain pharmaceutical sale relate otn consignment model abovementione agreement mckesson expire company financial result prior period quarterly comparison affect buildup orderly workdown wholesaler inventory application consignment model certain sale certain wholesaler addition respect sale account consignment model company financial result prior period quarterly comparison affect fluctuation buy pattern wholesaler include effect incentive offer correspond change inventory level maintain wholesaler wholesaler buy pattern wholesaler inventory level reflect underlie prescriber demand information pharmaceutical prescriber demand reference table compare change net sale restate basis estimate total retail mail order customer prescription growth certain company primary care pharmaceutical product company expect consignment model long apply respect sale cardinal mckesson buying pattern fluctuation inventory level wholesaler effect company financial result prior period quarterly comparison earning earning continue operation minority interest income taxis decrease million million case restate earning continue operation decrease million million case restate basic earning share decrease diluted earning share decrease case restate earning continue operation minority interest income tax million increase earning continue operation million increase case restate basic earning share dilute earning share increase respectively case restate year end december company record significant item affect comparability result period present set forth follow table discussion item note acquisition divestiture note restructure item note alliance investment restate consolidated financial statement restate restate restate dollar million inprocess research development charge restructure item gain sale businessesproduct line income taxis item million include million inventory writedown classify cost product sell million writeoff receivables reduction net sale million include million cost product sell company incur million cost relate dupont acquisition million include cost good sell gross margin respectively gross margin adversely impact generic competition change product mix less extent wholesaler sale incentive effective income tax rate earning continue operation restate basis compare negative effective income tax rate low pretax income primarily result writeoff acquire inprocess research development restructuring charge item month end september company recognize income tax benefit million settlement certain tax matter exist december determination company expect settlement ongoing tax litigation expense continue operation total cost expense percentage sale case restate cost product sell percentage sale increase case restate principally increase sale low margin product otn decline highermargin taxol buspar sale less extent increase wholesaler sale incentive cost product sell percentage sale decline compare case restate principally favorable manufacturing variance advertising promotion expense decrease prior year million primarily low spending taxol buspar advertising promotion expense increase million percentage sale restate advertising promotion expense decrease expense remain level marketing sell administrative expense percentage sale decrease case restate decrease result continued improvement costefficiencie company investment research development total million increase percentage sale increase compare case restate spending level reflect company commitment research broad range therapeutic area clinical development new product research development spending dedicated pharmaceutical product increase pharmaceutical sale restate compare respectively acquire inprocess research development include million writeoff relate dupont imclone transaction addition inprocess research development year include licensing payment relate product approve marketing alternative future use million million million respectively charge primarily relate payment otsuka pharmaceutical co ltd million abilify restructuring program implement downsize realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility program approximately employee terminate include sale force manufacture administration research personnel addition contract sale force terminate company exit nutritional business eastern europe pharmaceutical production facility research facility france result action company expect annual benefit earning continue operation minority interest income taxis approximately million future year action expect substantially complete early restructure program implement downsize realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility program approximately employee terminate include sale force manufacture administration research personnel addition company exit production facility certain international operation convatec research facility japan result action company expect annual benefit earning continue operation minority interest income taxis approximately million future year action substantially complete additional information restructuring note restructure item restate consolidated financial statementsin company recognize gain sale businessesproduct line million million million respectively describe note acquisition divestiture restate consolidated financial statement company divest corzide delestrogen florinef pharmaceutical product licensing right corgard estrace tablet apothecon commodity business viactiv solage product line company complete sale pharmaceutical productsestrace cream ovcon ovcon sea breeze brand japan company complete sale laboratori guieu spa italianbase gynecologic pediatric dermatologic product business company acquire calctose nutritional milk modifier product mexico business segment company operate reportable operating segmentspharmaceutical nutritional healthcare pharmaceutical pharmaceutical sale company large segment total company sale increase million restate sale growth result increase volume decrease effect foreign exchange rate fluctuation increase result change sell price pharmaceutical sale increase restate drive increase volume increase change sell price decrease effect foreign exchange rate fluctuation pharmaceutical sale increase million pharmaceutical sale increase million case restate increase reflect favorable impact previously disclose buildup wholesaler inventory company pharmaceuticals business impact restatement application consignment model certain sale large wholesaler pharmaceutical business additional information restatement application consignment model note restatement previously issue financial statement restate consolidated financial statement key pharmaceutical product sale restate include follow sale pravachol cholesterollowere agent company largestselle product increase million restate domestic sale increase million international sale increase foreign exchange negative impact million case restate december fda approve milligram version pravachol glucophage franchise sale increase million restate glucophage lead brand oral medication treatment noninsulin dependent type diabete see sale increase million restate company expect sale glucophage decline significantly generic metformin available january glucovance new oral combination drug glucophage extend release tablet sale million million respectively restate sale plavix platelet aggregation inhibitor increase million restate drive positive result cure study clopidogrel unstable angina prevent recurrent ischemic event publish new england journal medicine august sales avapro angiotensin ii receptor blocker treatment hypertension increase million restate avapro plavix cardiovascular product launch alliance bristolmyers squibb sanofisynthelabo sales taxol company lead anticancer agent decrease million restate international sale increase foreign exchange negative impact million restate lead strong sale japan france domestic sale decrease million restate generic competition taxol sale increase million restate sale paraplatin combination therapy treatment ovarian cancer decrease million increase million case restate sale monopril secondgeneration angiotensin convert enzyme ace inhibitor increase million decrease million case restate sale serzone novel treatment depression increase million decrease million case restate sale buspar antianxiety agent decrease million generic competition increase million case restate sale tequin quinolone antibiotic increase million million restate november fda approve tequin short course fiveday regimen treatment acute bacterial exacerbation chronic bronchitis sale videx antiretroviral agent increase million restate increase sale videx ec entericcoate beadlet launch videx sale increase million restate sale otn specialty distributor anticancer medicine relate product increase million million case restate follow table set forth comparison report net sale change restate basis estimate total retail mail order customer prescription growth certain company primary care pharmaceutical product estimate prescription growth amount base thirdparty datum significant portion company domestic pharmaceutical sale wholesaler change report net sale exceed prescription growth change net sale reflect underlie prescriber demand change change total change change total change change total net sale prescription net sale prescription net sale prescriptionspravachol glucophage plavix avapro monopril serzone cefzil buspar excess earning minority interest income taxis restate decrease million million result writeoff million acquire inprocess research development relate dupont imclone transaction decline taxol buspar sale result generic competition earning minority interest income taxis restate increase million million result increase sale price manufacture efficiency nutritional nutritional sale million restate comparable prior year level reflect decrease volume increase pricing decrease foreign exchange mead johnson continue leader infant formula market total infant formula sale restate increase foreign exchange favorable impact million sale enfamil company large selling infant formula increase million worldwide restate nutritional sale million restate comparable prior year level earning minority interest income taxis restate nutritional segment increase million million case restate primarily copromotion income cefzil pharmaceutical segment low promotion spending viactiv earning minority interest income taxis restate decrease million million low sale nonwic formula healthcare healthcare segment include convatec medical imaging business consumer medicine japan sales healthcare segment restate increase million include sale million medical imaging acquire october dupont acquisition healthcare sale increase result increase volume decrease effect foreign exchange change price healthcare segment sale restate decline million million primarily low ostomy sale healthcare sale business follow change restate restate restate dollar million convatec consumer medicine medical imaging na na total healthcare product earning minority interest income taxis restate increase million million primarily inclusion medical imaging business purchase october dupont acquisition earning minority interest income taxis restate increase million million discontinued operation describe note discontinued operation restate consolidated financial statement fourth quarter company complete sale clairol result pretax gain billion billion taxis restate gain include net gain disposal discontinue operation company spin zimmer holdings inc taxfree transaction result common stock dividend million restate represent net book value date spinoff company complete sale matrix essentials inc affiliate clairol result pretax gain million million tax restate gain include net gain disposal discontinue operation company record restructuring charge discontinue operation million taxis connection workforce reduction relate discontinued operation net earning discontinue operation include earning date divestiture decrease million million million geographic area bristolmyers squibb product available virtually country world company large market france japan germany italy canada sales increase restate product strong growth include glucophage plavix pravachol tequin avaprotaxol buspar sale decline generic competition sale restate increase primarily growth glucophage plavix buspar paraplatin avapro information pharmaceutical prescriber demand reference table compare change net sale restate basis estimate total retail mail order customer prescription growth certain company primary care pharmaceutical product sale europe mideast africa increase restate include negative effect foreign exchange result strong growth pravachol taxol france italy sales europe mideast africa decrease restate include negative effect foreign exchange pravachol taxol avapro plavix france italy spain experience strong growth increase partially offset decrease capoten sale generic competition sale western hemisphere country decreased restate include negative effect foreign exchange unfavorable impact foreign exchange feel primarily brazil underlie sale growth drive primarily increase sale mexico sale western hemisphere country increase restate include negative effect foreign exchange increase primarily result growth canada increase sale avapro enfamil mexico growth enfamil calctose sales pacific region decrease restate foreign exchange negative impact sale unfavorable impact foreign exchange feel primarily japan product strong growth include taxol paraplatin japan nutritional product philippine thailand china pacific region sale increase include positive effect foreign exchange result increase bufferin taxol paraplatin financial instrument company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument trading purpose gain loss hedge transaction offset gain loss underlying exposure hedge foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar japanese yen euro mexican peso canadian dollar table summarize company outstanding foreign exchange contract december fair value foreign exchange option contract estimate blackschole model base yearend currency rate fair value foreign exchange forward contract base yearend forward currency rate fair value option contract forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average notional strike price fair value maturity dollar million currency rate foreign exchange forward euro mexican peso japanese yen british pound taiwan dollar thai baht brazilian real hong kong dollar argentine peso total forwards foreign exchange option japanese yen canadian dollar australian dollar total option total contract december company hold righttosell option contract aggregate notional fair value million million respectively contract primarily relate option contract right sell euro mexican pesos brazilian real contract december primarily include option contract right buy japanese yen dollar aggregate notional fair value million primarily include option contract right buy japanese yen dollar aggregate notional fair value million million respectively company maintain cash cash equivalent time deposit marketable security financial institution financial institution locate primarily europe company policy design limit exposure financial institution contractual obligation payment period total dollar million shortterm borrowing longterm debt operating lease total discussion contractual obligation reference note shortterm borrowing longterm debt note financial instrument note lease restate consolidated financial statement march company imclone revise agreement reduce total payment million billion pursuant agreement company pay imclone million million million pay aggregate million achievement milestone discussion company agreement imclone note alliance investment restate consolidated financial statement recently issue accounting standard january financial accounting standard board fasb issue interpretation consolidation variable interest entity fin fin require variable interest entity consolidated company company subject majority risk loss variable interest entity activity entitle receive majority entity residual return fin require disclosure variable interest entity company require consolidate significant variable interest consolidation requirement fin apply immediately variable interest entity create january exist entity fiscal year interim period begin june certain disclosure requirement apply financial statement issue january regardless variable interest entity establish company process assess impact pronouncement consolidated financial statement base preliminary analysis impact fin company believe reasonably possible imclone meet criterion consider variable interest entity relation company accordingly company include require transitional disclosure fin note alliance investment restate consolidated financial statement december fasb issue sfas accounting stockbase compensationtransition disclosure sfas amend sfas accounting stockbase compensation provide alternative method transition voluntary change fair value base method accounting stockbase employee compensation addition sfas amend disclosure requirement sfas require prominent disclosure annual interim financial statement method accounting stock base employee compensation effect method report result provision sfas effective financial statement fiscal year interim period end december sfas material impact company consolidated financial statement adoption standard require company change company plan change fair value base method accounting stockbased compensation november fasb issue interpretation guarantor accounting disclosure requirement guarantee include indirect guarantee indebtedness fin fin require guarantor recognize liability inception guarantee fair value obligation undertake issuing guarantee include detailed disclosure respect guarantee type contract company enter meet scope interpretation financial performance standby letter credit behalf whollyowne subsidiary fin effective guarantee issue modify december initial adoption accounting pronouncement material effect company consolidated financial statement june fasb issue sfas accounting exit disposal activity effective exit disposal activity initiate december sfas address issue recognition measurement reporting cost associate exit andor disposal activity include restructuring activity currently account pursuant guidance emerge issue task force eitf set forth eitf issue liability recognition certain employee termination benefit cost exit activity include certain cost incur restructure sec set forth staff account bulletin restructuring impairment charge initial adoption account standard material effect company consolidated financial statement april fasb issue sfas supersede sfas requirement aggregate gain loss extinguishment debt classify material extraordinary item net relate income tax effect result criterion accounting principle board opinion classify gain loss sfas amend sfas require certain lease modification economic effect similar sale leaseback transaction account manner saleleaseback transaction restatement previously issue financial statement company adopt eitf issue account consideration give vendor customer include reseller vendor product january reflect cost certain vendor consideration eg cooperative advertising payment shelve allowance manufacturer coupon reduction revenue instead advertising product promotion expense effect eitf material company effective january company adopt provision sfas accounting impairment disposal longlive asset statement supersede sfas accounting impairment longlive asset longlive asset dispose accounting reporting provision apb opinion reporting result operationsreporte effect disposal segment business extraordinary unusual infrequently occur event transaction disposal segment business sfas address accounting use determine impairment longlive asset appropriate methodology recording impairment loss initial adoption statement materialimpact consolidate financial statement company june fasb issue sfas goodwill intangible asset effective fiscal year begin december company adopt sfas january certain provision apply early acquisition goodwill acquire intangible asset acquire june sfas address initial recognition measurement intangible asset acquire business combination recognition measurement goodwill intangible asset subsequent acquisition new rule goodwill indefinitelive intangible asset long amortize subject annual impairment test intangible asset continue amortize useful life accordance sfas goodwill indefinitelive intangible asset test impairment adoption standard annually sfas require goodwill test impairment twostep process step identify potential impairment second step measure impairment loss sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset goodwill deem impaired carrying report unit goodwill exceed estimate fair value intangible asset deem impaired net book value exceed estimate fair value goodwill arise business acquisition prior july amortize straightline basis period range year goodwill long amortize effective goodwill associate dupont acquisition future business combination amortize instead review impairment annually application nonamortization provision material effect company financial statement addition june fasb issue sfas accounting asset retirement obligation sfas fair value liability asset retirement obligation recognize period incur reasonable estimate fair value associated asset retirement cost capitalize carry longlive asset provision sfas effective financial statement fiscal year begin june initial adoption standard expect material impact company consolidated financial statement retirement benefit plan description company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan principal define contribution plan bristolmyer squibb saving investment program approximately total company define benefit pension plan asset liability hold plan asset plan hold single trust common asset allocation specify reference section total company plan plan international plan benefit company define benefit pension plan base primarily year credit service participant compensation asset company define benefit plan consist primarily equity fixedincome security december fair market value plan asset company define benefit plan million plan asset allocate equity security fix income security real estate investment december fair market value plan asset company define benefit plan million plan asset allocate equity security fix income security real estate investment bristolmyers squibb common stock represent asset plan end company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan asset allocation postretirement plan identical asset allocation describe define benefit pension plan accrual account significant assumption consistent gaap requirement set forth sfas employer accounting pension company account pension benefit accrual method recognize pension expense payment benefit retiree accrual method accounting pension benefit necessarily require actuarial assumption concern future event determine time benefit payment company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash fund actual result give year differ estimate economic factor assume discount rate company determine future pension obligation plan base indices aa aaarate corporate bond indice high quality corporate bond select reflect weightedaverage remain period benefit payment assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor net pension expense company define benefit pension plan include earning minority interest income taxis million include million curtailmentsettlement loss plan pension expense determine assumed discount rate assume rate compensation increase accumulate benefit obligation december plan determine assumed discount rate assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease byapproximately million assumed discount rate determine accumulate benefit obligation plan december reduce accumulate benefit obligation increase million determine expect longterm rate return plan asset company evaluate allocation asset expect return asset class company evaluate shortterm volatility context longterm nature pension commitment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million actual rate return earn plan asset year follow year return year return actual rate return earn plan asset discuss accounting principle provide difference expect actual return recognize average future service employee december company lower assume discount rate reflect decline yield high quality corporate bond assume rate compensation increase reflect expectation low inflation future consistent reduction assume discount rate reduction assume discount rate increase present value future benefit obligation accordingly effect increase plan pension expense contrast reduction assume rate compensation increase decrease present value benefit obligation accordingly effect decrease plan pension expense net pension expense company define benefit pension plan include earning minority interest income taxis expect million december company lower assume discount rate plan assume rate compensation increase plan aggregate revision effect increase present value future benefit obligation accordingly effect increase pension expense addition company revise base change expectation future termination retirement retirement turnover assumption revision effect decrease present value future benefit obligation accordingly effect decrease pension expense course year global equity market experience negative return negative equity market return compound market decline sp decline company evaluate market condition determine expect longterm rate return plan asset company determine reduce expect rate return plan asset december reduction expect result high pension expense approximately million company expect net pension expense define benefit pension plan include earning minority interest income taxis approximately million high reflect thing decrease assume discount rate expect longterm rate return outline decrease value asset company define benefit pension plan company assume discount rate expect longterm rate return plan asset calculate cost postretirement benefit calculate cost pension benefit delay recognition actuarial gain loss december unrecognize net actuarial loss company define benefit plan total million million respectively base fair market value plan asset compare unrecognized net actuarial gain million december unrecognized net actuarial loss reflect decline fair market value plan asset reduction weightedaverage discount rate sfas provide delay recognition actuarial gain loss include amount arise change estimate plan benefit obligation change assume discount rate difference actual expect return plan asset assumption change sfas require unrecognized net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value systematic rational manner year amortize pension income expense year extent unrecognize net actuarial gain loss exceed great project benefit obligation marketrelated value plan asset begin year net gain loss recognize pension income expense prospectively period approximate average remain service period active employee expect receive benefit plan approximately year extent offset loss gain subsequent year december unrecognize net actuarial gain determine base marketrelated value plan asset million exceed great project benefit obligation marketrelated value plan asset accordingly require amortize pension income december unrecognize net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation marketrelated value plan asset accordingly require amortize pension expense december unrecognize net actuarial loss determine base marketrelated value plan asset million exceed great project benefit obligation marketrelated value plan asset million offset future unrecognized gain high discount rate higher expect return plan asset amortization million expect increase pension expense follow year approximately million yearin event fair market value asset particular pension plan accumulate benefit obligation plan yearend gaap require additional minimum liability circumstance reduction stockholder equity establishment intangible asset december fair market value company define benefit pension plan asset million relate accumulate benefit obligation million december fair market value company define benefit pension plan asset decrease million relate accumulate benefit obligation increase million company recognize additional minimum liability approximately million million december company recognize additional minimum liability million december offset creation million intangible asset million reduction stockholder equity plan fund company funding policy define benefit plan contribute amount provide current service fund past service liability company contribute define benefit plan million million million respectively recent decline global equity market result decrease value asset company pension plan decline expect adversely affect company relate accounting result future period high pension expense increase cash funding requirement company contribute define benefit plan million include contribution million fourth quarter company contribution define contribution plan base employee contribution level company match company contribute principal define contribution plan million million million respectively company contribute principal define contribution plan million critical accounting policy company prepare financial statement accordance gaap preparation financial statement conformity gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow represent critical accounting policy summary company significant accounting policy include critical accounting policy discuss note accounting policy restate consolidated financial statement management company independent accountant discuss company critical accounting policy audit committee board director revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue sale shipment product customer case certain transaction pharmaceuticals wholesaler account consignment model gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net discount rebate estimate sale allowance accrual return consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis acquire inprocess research development fair value inprocess research development acquire business combination acquire iprd determine independent appraisal base present value research project project cash flow utilize income approach consistent aicpa practice aid asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximate company weight average cost capital impairment longlive asset company assess carry value goodwill identifiable intangible asset longlive asset annually event change circumstance indicate carry underlie asset recoverable circumstance include change company use underlie asset underperformance relative expect project result company assess recoverability future operation undiscounted cash flow impairment record present value future cash flow carry value asset estimate future cash flow base reasonable supportable assumption projection require management judgement change key assumption company business prospect change market condition result impairment charge equity investment company review equity investment impairment base determination decline market value investment value temporary making determination company consider accounting principle board opinion equity method accounting investment common stock set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company investment imclone subject accounting retirement benefit company pension plan postretirement benefit plan account actuarial valuation require sfas employer accounting pension sfas employer accounting postretirement benefit pension company consider accounting retirement plan critical management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect accumulate benefit obligation future cash fund detailed discussion company retirement benefit retirement benefit note retirement plan note postretirement benefit plan pension restate consolidated financial statement restructure downsize streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgement future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate result adjustment earning contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include product liability environmental liability tax matter accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate discussion contingency reference note income taxis note litigation matter restate consolidated financial statement income taxis december taxis provide approximately billion undistributed earning foreign subsidiary company invest invest undistribute earning indefinitely future earning repatriate united states company determine earning remit foreseeable future additional tax provision likely require complexity tax law assumption practicable estimate amount income taxis provide company evaluate need defer tax asset valuation allowance assess likely realize defer tax asset future assessment valuation allowance require require significant judgement include forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment addition company operation tax jurisdiction locate area world subject audit jurisdiction tax audits nature complex require year resolve accrual tax contingency require management estimate judgement respect ultimate outcome tax audit actual result vary estimate financial position cash cash equivalent time deposit marketable security total billion december compare billion december approximately billion cash cash equivalent time deposit marketable security hold company foreign subsidiary repatriation cash likely require additional tax provision reflect restate consolidated financial statement discussion matter critical accounting policiesincome taxis work capital restate billion december compare billion december result high accrue liability restructuring liability establish increase defer revenue consignment inventory cash cash equivalent time deposit marketable security conversion workingcapital item expect fund nearterm operation company cash cash equivalent time deposit marketable security december denominate primarily dollar instrument nearterm maturity average interest yield cash cash equivalent december respectively interest yield time deposit marketable security average respectively shortterm borrowing longterm debt december denominate primarily dollar include japanese yen longterm debt million result restatement company delay file quarterly report form q quarterly period end september quarter form q previously disclose delay result breach company delivery sec filing obligation indenture indenture company jpmorgan chase bank chase manhattan bank trustee company approximately billion longterm debt outstanding certain credit agreement give certain right trustee indenture respective lender credit agreement accelerate maturity company indebtedness trustee respective lender exercise right accelerate filing quarter form q concurrently file cure noncompliance abovementione obligation indenture credit agreement accordingly debt outstanding indenture credit agreement long accelerate classified current company consolidated balance sheet company longterm credit rating moody standard poor credit rating agency reduce aaaaaa aa aa respectively december moody place company longterm shortterm debt rating review possible downgrade company hold discussion moody provide additional information request facilitate review time company rating remain credit review moody action take internally generate cash provide operation restate basis billion billion billion cash provide operation continue company primary source fund finance operating need expenditure new plant equipment company ongoing commitment improve plant efficiency maintain superior research facility company invest billion capital expansion past year cash flow operation include product liability payment pension contributionscash provide operation past year pay dividend billion finance billion company share repurchase program fund business acquisition include purchase patent trademark cost million company share repurchase program authorize company purchase common stock time time open market private transaction market condition permit company purchase million share common stock cost billion bring total share acquire program inception million share past year company repurchase million share cost billion employment level december increase prioryear level result dupont acquisition cautionary factor affect future result annual report include document incorporate reference write oral statement company make time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include factor delay divert change year possible predict identify factor include follow new government law regulation health care reform initiatives united states state federal level country ii change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available united states certain foreign country iv new law regulation judicial decision affect pricing marketing competitive factor new product develop competitor low price superior performance feature competitive bristolmyer squibb current product ii generic competition company product mature patent expire product iii technological advance patent attain competitor iv problem licensor supplier distributor v business combination company competitor major customer difficulty delay inherent product development manufacturing sale product appear promise development fail reach market numerous reason include efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture ii seizure recall product iii failure obtain imposition limitation use loss patent intellectual property right iv failure comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture v manufacturing distribution problem legal difficulty preclude delay commercialization product adversely affect profitability include intellectual property dispute ii adverse decision litigation include product liability commercial case iii inability obtain adequate insurance respect type liability iv recall pharmaceutical product force closing manufacture plant v government investigation vi claim assert violation security antitrust law vii environmental matter viii tax liability increase pricing pressure worldwide include rule practice manage care group institutional governmental purchaser judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement pricing general fluctuation buy pattern inventory level major distributor retail chain trade buyer result seasonality pricing wholesaler buying decision include effect incentive offer company wholesaler inventory management policy include workdown wholesaler inventory level factor great expect cost difficulty include unanticipated effect difficulty acquisition disposition event include obtain regulatory approval occur connection evolve business strategy legal defense cost insurance expense settlement cost risk adverse decision relate litigation change advertise promotional spend category spending affect sale change company structure result acquisition divestiture merger restructuring strategic initiative economic factor company control change business economic condition include limited change interest rate fluctuation foreign currency exchange rate change business political economic condition recent terrorist attack threat future terrorist activity part world relate military action overseas change accounting standard promulgate financial accounting standard board securities exchange commission american institute certify public accountant require adjustment financial statement company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event item restate financial statement supplementary datum restate consolidated financial statement supplementary datum include note restate consolidated financial statement set forth item revise reflect restatement company business segment reorganization effective quarter certain event occur subsequent filing original bristolmyer squibb company consolidate statement earning dollar million share datum restate restate restate earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure item gain sale businessesproduct line incomeexpense net earning continue operation minority interest income taxis provision income taxis minority interest net taxis earning continue operation discontinue operation net earning net gain disposal net earning earning common share basic earning continue operation discontinue operation net earning net gain disposal net earning dilute earning continue operation discontinue operation net earning net gain disposal net earning average common share outstanding basic dilute dividend declare common share include minority interest expense income unconsolidate affiliate accompany note integral financial statement bristolmyers squibb company consolidate statement comprehensive income retain earning dollar million restate restate restate comprehensive income net earning comprehensive income foreign currency translation net tax benefit taxis month end december tax benefit defer loss derivative qualify hedge net tax benefit total comprehensive loss comprehensive income retain earning retain earning january net earning cash dividend declare zimmer common stock dividend retain earning december accompany note integral financial statement bristolmyers squibb company consolidate balance sheet dollar million december restate restate asset current asset cash cash equivalent time deposit marketable security receivables net allowance inventory include consignment inventory prepay expense total current asset property plant equipment net goodwill intangible asset net asset total asset liability current liability shortterm borrowing defer revenue consign inventory account payable dividend payable accrue expense accrue rebate return foreign income taxis payable total current liability liabilitie longterm debt total liability commitment contingency stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share issue issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock common share total stockholder equity total liability stockholder equity accompanying note integral financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december restate restate restate cash flow operating activity net earning depreciation amortization acquire inprocess research development provision restructure item gain sale businessesproduct line include discontinued operation operate item receivables inventory defer revenue consign inventory account payable accrue expense income taxis product liability insurance recoverable pension contribution asset liability net cash provide operating activity cash flow invest activity proceed sale time deposit marketable security purchase time deposit marketable security addition property plant equipment proceed sale businessesproduct line proceed sale clairol acquisition dupont investment imclone business acquisition include purchase trademarkspatent net net cash provide investing activity cash flow financing activity shortterm borrowing longterm debt borrowing longterm debt repayment issuance common stock stock plan purchase treasury stock dividend pay net cash provide financing activity effect exchange rate cash increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral financial statement bristolmyers squibb company note restate consolidated financial statement note restate consolidated financial statement reference amount reflect balance amount restate basis intercompany balance transaction eliminate note accounting policy basis consolidationthe consolidated financial statement include account bristolmyer squibb company majority own subsidiary use estimatesthe preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability estimate apply revenue recognition policy accounting retirement postretirement benefit include actuarial assumption actual result differ estimate result revenue recognitionthe company recognize revenue sale shipment product customer case certain transaction pharmaceuticals wholesaler account consignment model gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis revenue reduce time sale reflect expect return estimate base historical experience additionally provision time sale discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue sale rebate return accrualsmedicaid manage healthcare sale rebate sale return accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate prime vendor chargeback establish similar manner record reduction account receivable cash cash equivalentscash cash equivalent primarily include security maturity month time purchase record cost approximate market value time deposit marketable securitiestime deposit marketable security available sale record fair value approximate cost inventory valuationinventorie generally state average cost excess market capital asset depreciationexpenditure addition renewal improvement capitalize cost depreciation generally compute straight line method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry valueof depreciable asset recoverable estimate undiscounted future cash flow produce asset appropriate group asset compare carry value determine impairment exist capitalize softwarecertain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur investmentsthe company consolidate majority own subsidiary company account own company ability exercise significant influence equity method accounting company share net income loss equity investment include minority interest expense consolidate statement earning company periodically review equity investment impairment adjust investment fair value decline market value deem temporary longterm investment security comprise marketable equity security security investment market value readily available include asset marketable equity security classify availableforsale report fair value fair value base quote market price end reporting period unrealize gain loss report net relate tax effect component accumulate comprehensive income loss stockholder equity sell time sale gain loss calculate specific identification method recognize incomeexpense loss recognize income decline market value deem temporary security investment market value readily available carry cost acquisitionsthe company adopt sfas business combination statement require company use purchase method accounting business combination initiate june goodwillin june financial accounting standard board fasb issue sfas goodwill intangible asset effective fiscal year begin december sfas address initial recognition measurement intangible asset acquire outside business combination recognition measurement goodwill intangible asset subsequent acquisition new rule goodwill long amortize subject annual impairment test connection accounting change goodwill result company dupont pharmaceutical acquisition imclone investment amortize goodwill arise business acquisition prior july amortize straightline basis period range year goodwill amortize december begin january goodwill amortization expense long record goodwill amortization expense million intangible assetsintangible asset consist patent technology license amortize straightline basis period range year represent remain life asset accumulate amortization intangible asset million december million december amortization expense intangible asset million million million respectively intangible asset periodically review impairment base assessment future operation include cash flow asset identify impair write fair market value acquire inprocess research developmentthe fair value inprocess research development acquire business combination determine independent appraisal base present value research project project cash flow utilize income approach consistent aicpa practice aid asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximate company weight average cost capital acquire process research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur income taxesthe provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize company record provision income taxis undistribute earning foreign subsidiary expect repatriate foreseeable future product liabilityaccrual product liability record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize insurance recoverable record balance sheet general payment term year amount recognize excess relate liability december million million respectively derivative financial instrumentsderivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument trading purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize charge credit earning derivative designate cash flow hedge effective portion change fair value derivative record comprehensive income loss recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earningsthe company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company recognize gain loss designate hedge financial instrument shipping handle coststhe company typically charge customer shipping handle cost shipping handling cost include marketing sell administrative expense million million million respectively advertising costsadvertising cost expense incur advertising expense million million million respectively stockbase compensationthe company apply accounting principle board apb opinion accounting stock issue employee relate interpretation accounting stockbase compensation plan company recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire earning sharebasic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option note restatement previously issue financial statement company experience substantial buildup wholesaler inventory pharmaceutical business year primarily buildup primarily sale incentive offer company wholesaler incentive generally offer end quarter order incentivize wholesaler purchase product sufficient meet company quarterly sale projection establish company senior management april company disclose substantial buildup develop subsequently undertake plan work orderly fashion wholesaler inventory level late october base review consideration previously disclose buildup wholesaler inventory company pharmaceutical business incentive offer certain wholesaler advice company independent auditor pricewaterhousecooper llp company determine require restate sale earning correct error time revenue recognition certain sale certain pharmaceuticals wholesaler time company undertake analysis transaction incentive practice pharmaceuticals wholesaler company determine certain incentivize transaction certain wholesaler account consignment model recognize revenue transaction shipment determination involve evaluation variety criterion number complex accounting judgment result analysis company determine certain sale large wholesaler pharmaceutical business account consignment model base relationship incentive offer wholesaler inventory hold wholesaler follow determination restate sale earning matter describe company determine correct certain historical accounting policy conform accounting gaap certain know error application gaap previously record case company believe error material company consolidated financial statement addition restatement process company investigate accounting practice certain area involve significant judgment determine restate additional item respect company conclude error application gaap include certain revision inappropriate account senior management set aggressive target company business error inappropriate accounting correct restatement arise period unrealistic expectation consequent overestimation anticipate performance certain company product program result forego company restate financial statement year end december include correspond interim period quarterly period end march june restatement affect period prior impact restatement prior period reflect adjustment opening retain earning january connection audits restatement previously issue financial statement company consolidated financial statement year end december company independent auditor pricewaterhousecooper llp identify communicate company audit committee material weakness define standard establish american institute certify public accountant relate company accounting public financial report significant matter initial recording management review oversight certain accounting matter year company search hire new chief financial officer outside company restaffe controller position create position chief compliance officer change leadership pharmaceutical group response wholesaler inventory buildup matter identify restatement adjustment direction audit committee year senior management direct company dedicate resource step strengthen control process procedure order identify rectify past accounting error prevent recurrence circumstance result need restate prior period financial statement company revise budgeting process emphasize bottomup approach contrast topdown approach company implement review certification process annual quarterly report security exchange act amend process design enhance monitor wholesaler inventory addition company process expand business risk disclosure group include senior management include chief executive officer chief financial officer take number additional step design create open environment communication flow information company company continues identify implement action improve effectiveness disclosure control procedure internal control include plan enhance resource training respect financial reporting disclosure responsibility review action audit committee independent auditor set forth restatement adjustment include restatement previously issue financial statement error mean accounting principle board opinion accounting changesrevenue recognition restatement adjustment consignment sale historically company recognize revenue sale shipment product customer gaap revenue recognize substantially risk reward ownership transfer case sale wholesaler result incentive excess wholesaler ordinary course business inventory level time understand agreement course deal consistent business practice company extend incentive base level excess inventory connection future purchase time incentive cover substantially vary directly wholesaler cost carry inventory excess wholesaler ordinary course business inventory level substantially risk reward ownership transfer shipment accordingly sale account consignment model analysis base staff accounting bulletin revenue recognition financial statement topic question sec observer comment eitf issue vendor income statement characterization consideration pay resell vendor product codify eitf issue example payment reseller financing cost determination sale wholesaler meet forego criterion involve evaluation variety factor number complex judgment consignment model company recognize revenue shipment product shipment product company invoice wholesaler record defer revenue gross invoice sale price classifie inventory hold wholesaler consignment inventory company cost inventory company recognize revenue net discount rebate estimate sale allowance accrual return consignment inventory long subject incentive arrangement later inventory sell wholesaler customer firstin firstout fifo basis company restate previously issue financial statement correct timing revenue recognition certain previously recognize pharmaceutical sale cardinal mckesson large wholesaler company pharmaceuticals business base application criterion describe record error time shipment account consignment model company determine shipment product cardinal shipment product mckesson meet consignment model criterion set forth july july respectively case continue end period accordingly consignment model require apply shipment prior respective period company recognize revenue respect sale cardinal mckesson shipment product company generally view approximately month supply desirable level wholesaler inventory goingforward basis level wholesaler inventory representative industry average apply consignment model sale cardinal mckesson company define inventory excess wholesaler ordinary course business inventory level inventory week week supply respectively base level inventory cardinal mckesson require basis negotiation incentive grant result restatement adjustment net sale reduce million million million respectively correspond reduction earning continue operation minority interest income tax million million million respectively separately discussion march company enter distribution agreement mckesson provision warehousing order fulfillment service company oncology therapeutic network otn specialty distributor anticancer medicine relate product term agreement mckesson purchase oncology product service otn fulfillment need number vendor include company subsequent shipment product mckesson company significant continue involvement transaction include marketing product enduser invoicing customer collect receivables customer behalf mckesson addition otn keep credit risk responsible shipping cost customer prior restatement company record error sale agreement shipment product mckesson company restate previously issue financial statement account sale consignment model defer recognition revenue product sell mckesson result reduction net sale earning continue operation minority interest income taxis million million respectively year end december sale return historically company record return base actual product return period accounting policy accordance gaap accordingly error company believe error material time level return consistently low absolute dollar basis company practice historically approximate accrual method accounting material respect restatement company adopt accrual method accounting return conform gaap restatement adjustment reduce opening retain earning january million effect amount affect period prior reduce net sale earning continue operation minority interest income taxis year end december million million million respectively sale rebate accrual company restate medicaid prime vendor rebate liabilitie pharmaceuticals business correct error determination accrual important component determine require accrual estimate inventory wholesaler sell company expect pay rebate company experience substantial buildup wholesaler inventory pharmaceutical business year primarily accrual fully reflect growth inventory level quarter company determine estimate medicaid prime vendor sale rebate accrual balance pharmaceuticals business understate record onetime adjustment accrual result decrease sale earning approximately million million respectively restatement company correctly consider inventory wholesaler reverse previously record quarter onetime adjustment restatement attributable impact consignment sale adjustment deferral certain previously recognize sale result deferral recording relate rebate company record restatement adjustment correct error methodology establish manage healthcare sale rebate accrual accrue estimate rebate time sale ratably period manage health care entity perform obligation agreement provide rebate medicaid prime vendor rebate discuss estimate inventory wholesaler sell company expect pay rebate important component determine require accrual previously impact excess inventory hold wholesaler erroneously consider determination accrualthe restatement adjustment medicaid prime vendor manage care rebate reduce opening retain earning january million effect amount affect period prior reduce net sale earning continue operation minority interest income taxis year end december million increase net sale year end december million increase net sale earning continue operation minority interest income taxis year end december million million respectively restatement adjustment capitalize research development payment prior company investment imclone fourth quarter company accounting policy payment relate acquisition license patent right capitalize payment regardless underlie asset receive marketing approval fda regulatory agency company prior accounting policy base principle payment acquire license product capitalize amortized period company expect benefit revenue stream associate underlie product research development term depend arrangement capitalize payment subsequently amortize earning straightline method term agreement expect life underlie product policy accordance gaap accordingly error gaap require incur cost relate acquisition licensing product receive regulatory approval market alternative future use charge earning restatement company correct accounting policy payment relate acquisition license patent right conform gaap result opening retain earning reduce january million effect amount affect period prior earning continue operation minority interest income taxis year end december increase million million respectively earning continue operation minority interest income taxis year end december reduce million irbesartan transaction fourth quarter company sanofisynthelabo sanofi modify exist codevelopment arrangement irbesartan avapro form alliance company contribute irbesartan intellectual property company own interest sanofi own interest profit share proportion ownership interest sanofi agree pay company million million fourth quarter respectively company account transaction sale interest license defer amortize million payment income expect useful life license company previous accounting base determination useful life license anticipate fda approval compete product company review accounting transaction determine previous amortization base anticipate approval compete product accordance gaap accordingly error approval compete product receive restatement company correct error amortize million payment remain patent life approximately year consequently earning continue operation minority interest income taxis year end december reduce million acquisition liability company record certain liability contingency identify date acquisition connection acquisition period subsequent period substantial portion liability determine excess reversed income amount relate dupont acquisition reverse goodwill base investigation accounting practice certain area involve significant judgment company determine certain portion liability establish inappropriately appear related quantifiable specific category liability support establishment portion liability amount ultimately inappropriately reverse restatement company adjust goodwill liability date acquisition reverse amount inappropriately recognize income subsequent period addition company record error million acquisition cost paidin capital connection acquisition redmond products inc lead hair care manufacturer account poolingofinterest accounting method company determine classification cost paidin capital error million charge expense result decrease opening retain earning january base investigation accounting practice certain area involve significant judgment company determine remain million establish inappropriately appear related quantifiable specific category liability support establishment million restate describe follow table present amount pretax acquisition reserve inappropriately establish reversed income year reserve amounts inappropriately inappropriately establish reverse dollar million pre total aggregate effect restatement transaction decrease opening retain earning january approximately million effect amount affect prior period addition adjustment redmond acquisition describe increase additional paidin capital component stockholder equity million adjustment decrease goodwill million decrease earning continue operation minority interest income tax million million year end december respectively divestiture liabilitiesin connection divestiture transaction consummate period company record certain liability contingency identify date divestiture subsequent period substantial portion liability determine excess reversed income base investigation accounting practice certain area involve significant judgment company determine certain portion liability establish inappropriately appear quantifiable specific category liability support establishment portion liability amount ultimately inappropriately reverse accordingly company eliminate amount inappropriately recognize income subsequent period increase gain sale period relate divestiture equal addition company determine certain liability inappropriately establish reduction equity connection spinoff zimmer accordingly company reverse establishment liability follow table present amount pretax divestiture reserve inappropriately establish reversed income year reserve amounts inappropriately inappropriately establish reverse dollar million pre total include reserve inappropriately establish inappropriately reverse million million respectively relate discontinued operation represent amount inappropriately reverse amount correct restatement restatement adjustment increase opening retain earning january million effect amount affect period prior decrease earning continue operation minority interest income tax million million year end december respectively increase earning continue operation minority interest income taxis million year end december addition net gain sale discontinue operation increase million million year end december respectively zimmer spinoff dividend decrease million corresponding decrease accrue liability restructure item period company record restructure asset writedown charge connection decision exit certain activity streamline operation base investigation accounting practice certain area involve significant judgment company determine certain charge establish error include inappropriately establish classified provision restructure item statement earning restatement respect company reverse million million record restructuring expense liability establish error million relate liability inappropriately establish asset writedown restructuring expense primarily manufacture facility closure management commit million expense relate discontinued operation erroneously record restructuring expense charge partially offset million item inappropriately charge restructure liability million cost inappropriately establish error restructure expense respect certain operating expense item establish restructuring expense error previously correct error material company consolidated financial statement addition certain operating item million inappropriately classify error restructuring expense million relate discontinued operation company determine million restructuring charge relate closure research facility classify error research development expense addition company reclassify certain writeoff inventory connection restructuring action million million respectively restructure expense cost product sell bristolmyers squibb company note restate consolidated financial statement note restatement previously issue financial statement continue company record error writeoff certain receivable exit product line approximately million restructure non recur charge company record restatement adjustment properly record writeoff receivables reduction net sale aggregate adjustment restructuring item result increase earning continue operation minority interest income tax million million year end december respectively litigation accrual adjustment sunday march company enter bind letter agreement watson pharmaceuticals inc settle lawsuit relate buspar gaap million charge incur letter agreement accrue fourth quarter letter agreement enter prior original issuance consolidated financial statement file april company erroneously accrue million charge quarter restatement company restate charge recognize fourth quarter accordingly earning continue operation minority interest income taxis year end december reduce million relate busparlitigation income taxis sfas impact record intercompany sale inventory relate product ultimately sell unrelated party intercompany sale consolidated subsidiary locate different tax jurisdiction current tax expense liability recognize country sale correspond offset defer tax benefit asset recognize offset tax product sell unrelated party restatement company record adjustment correct erroneous calculation defer tax asset relate intercompany profit inventory intercompany royalty reflect impact intercompany profit inventory intercompany royalty consignment sale restatement adjustment discuss restatement adjustment reduce opening retain earning january million decrease net earning million increase net earning million million respectively cumulative adjustment net defer tax asset increase million december net decrease million million december respectively fourth quarter company erroneously reduce defer tax benefit relate acquire inprocess research development inappropriate conclusion realization relate defer tax asset company erroneously determine defer tax asset associate purchase price premium pay tender offer imclone stock record uncertainty realization company restate defer tax asset fourth quarter recognize defer tax benefit million additionally company recognize excess liability relate income tax contingency error determine interest relate record tax liability error result use incorrect interest rate restatement company restate income taxis payable december recognize current benefit million reflect tax impact pretax restatement adjustment describe income tax expense adjust restate annual period tax impact restatement adjustment increase opening retain earning million january reduce tax provision increase earning continue operation include taxis minority interest million million million year end december respectively tax provision increase net earning discontinue operation reduce million million result restatement adjustment cumulative adjustment relate pretax adjustment item continue operation include minority interest increase net defer tax asset million million million december respectively dividend accrual historically company recognize liability declare dividend record date typically approximately week declaration date accounting policy accordance gaap accordingly error declaration lawful dividend create law state company incorporation obligation corporation declaration date require recognition dividend accrual date restatement company correct accounting policy record liability dividend declaration date restatement result reduction million opening retain earning january effect amount affect period prior correspond increase dividend payable stockholder equity dividend payable similarly restate million million million year end december respectively revision restatement item quarter company enter likekind exchange agreement respect certain aircraft erroneously recognize pretax gain million time recognize excess proceed receive tradein record net book value gain reduction basis new aircraft restatement company correct error result decrease million opening retain earning january effect amount affect prior period reflect reduction book value aircraft acquire million addition company determine portion accrue liability employee medical benefit inappropriately reverse certain insurance retirement cost inappropriately charge discontinued operation correct error restatement adjustment increase earning continue operation minority interest income taxis year end december million million respectively summary restatement item follow table present effect restatement adjustment net sale increase decrease net sale year end december dollar million net sale previously report adjustment consignment sale sale return sale rebate accrual restructure item decrease net sale net sale restate result restatement application consignment model approximately million sale calculate net customary early pay cash discount recognize error period reverse approximately million expect recognize approximately million project recognize follow table present effect restatement adjustment earning continue operation minority interest income taxis earning continue operation net earning gain sale discontinue operation year end december dollar million earning continue operation minority interest income taxis previously report revenue recognition restatement adjustment consignment sale sale return sale rebate accrual subtotal restatement adjustment capitalize research development payment irbesartan transaction acquisition liability divestiture liability restructure item litigation accrual adjustment restatement item subtotal total restatement adjustment earning continue operation minority interest income taxis restate provision income taxis previously report tax relate restatement adjustment tax restatement adjustment minority interest net taxis earning continue operation restate net earning gain disposal discontinue operation previously report adjustment divestiture liability net earning gain disposal sale discontinue operation restate minority interest include expense pretax basis originally report minority interest show income unconsolidate affiliate net taxis earning continue operation income taxis consolidate statement earning amount previously report reclassify comparable basis follow table present impact restatement adjustment affect period prior stockholder equity january increase decrease stockholder equity dollar millions stockholder equityjanuary previously report sale return sale rebate accrual capitalize research development payment acquisition liability divestiture liability restatement item defer taxis intercompany profit dividend accrual decrease stockholder equity stockholder equityjanuary restate follow table present impact restatement adjustment company previously report result condense basis year end december previously previously previously report restate report restate report restate dollar million share datum statement operation net sale total cost expense earning continue operation discontinue operation net earning net gain disposal net earning basic earning common share continue operation discontinue operation net earning net gain disposal net earning dilute earning common share continue operation discontinue operation net earning net gain disposal net earning balance sheet cash marketable security receivables net inventory include consignment inventory prepay expense total current asset property plant equipment net goodwill intangible asset net asset total asset shortterm debt borrowing defer revenue consign inventory current liability total current liability longterm debt longterm liability total liability stockholder equity total liability stockholder equity bristolmyers squibb company note restate consolidated financial statement note discontinued operation company announce plan divestiture clairol zimmer business accordingly operation clairol include matrix essentials inc matrix affiliate zimmer reflect discontinued operation consolidated statement earning november company complete sale clairol procter gamble cash proceed approximately billion sale result pretax gain billion billion taxis restate include gain disposal discontinue operation august company spin zimmer holdings inc taxfree distribution result common stock dividend million restate company complete sale matrix cosmair inc wholly own subsidiary sa result pretax gain million million taxis restate gain include gain disposal discontinue operation net sale earning discontinue operation follow dollar million net sale earning income taxis income taxis net earning discontinue operation earning income taxis year end december include restructure charge million consolidated balance sheet consolidate statement cash flow include clairol zimmer business date disposition net asset discontinue operation december million consist current asset million longterm asset million liability principally current million company use centralized approach cash management financing operation accordingly company allocate debt business cash flow operate investing activity discontinue operation year end december billion include approximately billion proceed sale clairol million include million proceed sale matrix million respectively note acquisition divestiture dupont pharmaceuticals acquisition october company acquire dupont pharmaceutical business dupont e du pont de nemour company billion cash result dupont include consolidated financial statement date acquisition dupont primarily domestic pharmaceutical imaging product business focus research development acquisition finance proceed issuance billion commercial paperthe issuance billion mediumterm note internal cash flow purchase price allocation prepare preliminary basis certain change expect additional information available follow summary estimate fair value asset acquire liability assume date acquisition restate dollar million current asset property plant equipment intangible asset acquire inprocess research development goodwill asset total asset acquire current liability restructure liability acquisition liability long term liability total liability assume purchase price total intangible asset million amortize weightedaverage useful life include core develop technology million year weightedaverage useful life respectively patent million year weightedaverage useful life goodwill million assign pharmaceutical report unit total million expect deductible tax purpose year period value million assign acquire inprocess research development charge earning fourth quarter charge associate research project cardiovascular central nervous system oncology antiinfective therapeutic area range preclinical phase ii development stage determine identify research project technological feasibility establish alternative future use project fda approval date year time company expect project begin generate cash flow cost complete research project estimate billion research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda approval company terminate project antiinfective therapeutic area connection acquisition company record million restructuring liability result severance relocation workforce elimination duplicate facility contract termination cost recognize company liability assume acquisition date result additional goodwill restructuring liability consist million employee termination benefit approximately employee million related closure facility million contract termination million originally record accrue expense reduce million december follow unaudited pro forma financial information present result acquisition occur begin respective period restate restate dollar million share datum net sale net earning earning sharebasic earning sharedilute pro forma result prepare comparative purpose include certain adjustment additional amortization expense result identifiable intangible asset arise acquisition increase interest expense acquisition debt pro forma net earning earning share amount include billion gain sale clairol pro forma result necessarily indicative result operation actually resulted acquisition effect begin respective period future result company complete sale corzide delestrogen florinef pharmaceutical product licensing right corgard estrace tablet apothecon commodity business viactiv solage product line result pretax gain million company complete sale pharmaceutical productsestrace cream ovcon ovcon sea breeze brand japan result pretax gain million june company acquire calctose nutritional milk modifier million september company enter development andcommercialization agreement aripiprazole novel drug study phase iii trial treatment schizophrenia otsuka pharmaceutical co ltd connection agreement company payment million million expense inprocess research development december company complete sale laboratori guieu spa gynecologic pediatric dermatologic product business headquartered milan italy pretax gain million bristolmyer squibb company note restate consolidated financial statement note restructure item activity company record pretax restructuring charge restate basis million restructuring program include termination benefit asset writedown cost implement downsize streamline operation rationalize manufacture facility terminate certain sale force research contract obligation time record action expect substantially complete month expect substantially complete early additional cost associate restructuring project year include million deduction customer charge back relate abandon nonstrategic pharmaceutical product line include reduction sale restate million relate inventory writeoff include cost product sell restate current year restructuring charge offset reversal million result change estimate relate separation cost cancellation project previously provide charge restate consist million employee termination benefit approximately employee severance action result company wide restructuring effort downsize streamline operation impact virtually area include sale force manufacture administration research personnel addition million accrue termination contract sale force million accrue exit cost primarily relate cost associate closure certain manufacturing operation charge include million fix asset writedown million asset writedown primarily related exit nutritional business eastern europe closure pharmaceutical production facility closure research facility france follow table present detail charge restate operating segment type company allocate restructuring charge business segment restate restate employee asset restate restate employee termination write exit restate termination benefit down cost item total dollar million employee termination datum pharmaceutical nutritional healthcare corporateother total reduction reserve change estimate restructure item reflect statement earning item record restate include pretax charge million settlement litigation promotion claim bring distributor store brand infant formula meadjohnson buspar patent litigation million contribution bms foundation million establish additional reserve future breast implant claim million cost associate product recall activity company record pretax restructuring charge restate million restructuring program include termination benefit asset writedown cost implement consolidate sale force rationalize manufacturing facility downsize streamline operation additional cost associate restructuring project year include million relate inventory writeoff include cost product sell restate action substantially complete charge restate consist million employee termination benefit approximately employee severance action focus sale force manufacture administrative personnel addition million cost record consist mainly certain contract termination facility remediation expense charge include million asset writedown primarily related exit research facility japan manufacturing operation certain international operation convatec addition asset million write consist primarily capitalize software long result sale force action describe follow table present detail charge restate operating segment type company allocate restructuring charge itsbusiness segment restate restate restate employee asset employee termination write exit restate restate termination benefit down cost item total dollar million employee termination datum pharmaceutical nutritional healthcare corporateother total item record restate include million contribution bms foundation million cost associate product recall follow table present restructure charge spend liability associate prior current action restate restate employee termination exit cost restate liability liability total dollar million balance december charge spend change estimate balance december charge spend change estimate balance december note earning share computation basic earning common share dilute earning common share follows restate restate restate dollar share million share datum net earning continue operation discontinue operation net earning net gain disposal net earning basic average common share outstanding earning continue operation discontinue operation net earning net gain disposal net earning dilute average common share outstanding incremental share outstanding assume exercise dilutive stock option weight average sharesdilute earning continue operation discontinue operation net earning net gain disposal net earning weightedaverage share issuable exercise stock option include diluted earning share calculation dilutive million million million note income expense year end december restate restate restate dollar million interest income interest expense foreign exchange gain loss net income expense net interest pay million million million respectively net primarily amortization goodwill capitalize software partially offset insurance settlement royalty income net include payment relate product collaboration agreement ivax corporation note alliance investment november company purchase million share imclone system incorporate imclone share million represent approximately imclone share outstanding prior commencement public tender offer transaction account equity method accounting imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include arrangement codevelop copromote investigational cancer drug erbitux series payment total billion company pay imclone milestone payment million march agreement imclone revise reduce total payment million billion revise agreement company pay imclone million quarter million march pay aggregate million achievement milestone revise agreement company pay imclone distribution fee base flat rate product revenue north america fourth quarter transaction result pretax charge approximately million comprise million writeoff acquire process research development relate equity investment million writeoff portion million milestone payment remain million million milestone payment record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone million milestone payment revise agreement million expense inprocess research development quarter remain million record additional equity investment eliminate income statement effect portion milestone payment company economic claim ownership interest imclone acquire inprocess research development charge relate oncology research project phase later stage development research project erbitux late phase iii development determine identify research project area technological feasibility establish alternative future use project food drug administration fda approval date year time company expect project begin generate cash flow cost complete project estimate million research development project consider valuation subject normal risk uncertainty associate demonstrate safety efficacy require obtain fda approval purchase price allocation result million patent technology intangible asset amortize overtheir weightedaverage useful life year approximately million goodwill amortize december imclone announce fda refuse accept filing biologic license application bla submit imclone erbitux bla submit gain marketing approval treat irinotecanrefractory colorectal carcinoma january subcommittee oversight investigation house energy commerce committee announce investigate question conduct imclone development erbitux january imclone announce receive informal inquiry security exchange commission inquiry department justice aforementione subcommittee company cooperate investigation million pay equity investment million milestone payment million million expense acquire inprocess research development remain million record equity investment additional million record investment primarily acquisition cost result carry value million december pershare basis carry value company imclone investment closing market value imclone share december respectively quarter company record pretax charge earning million temporary decline market value imclone fair value equity investment imclone determine charge base market value imclone share september december imclone total asset million total stockholder deficit million accumulate deficit million year end december imclone million net loss company process assess impact fasb interpretation consolidation variable interest entity consolidate financial statement base preliminary analysis impact fin company believe reasonably possible imclone meet criterion consider variable interest entity relation company company sanofisynthelabo sanofi enter codevelopment comarketing agreement product avapro irbesartan angiotensin ii receptor antagonist indicate treatment hypertension plavix clopidogrel platelet inhibitor worldwide alliance operate framework geographic territory america australia europe asia territory partnership form manage central expense market research development royalty supply finish product individual country country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place company act operating partner territory cover america principally canada puerto rico latin american countries australia own majority control interest territory company consolidate country partnership result territory record sanofi share result minority interest expense company record sale territory comarkete country million million million respectively case restate sanofi act operating partner territory cover europe asia own majority control interest territory company account investment partnership entity territory equity method record share result net income unconsolidate affiliate include minority interest net taxis income taxis partnership entity year end december million million million respectively note income taxis component earning loss continue operation minority interest income taxis year end december restate restate restate dollar million nonus amount categorize base location tax authority provision income taxis attributable continue operation consist year end december restate restate restate dollar million current nonus deferredus nonus company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis restate restate restate dollar million earning continue operation minority interest income tax statutory rate effect operation ireland puerto rico switzerland state local taxis foreignother effective tax rate continue operation decline primarily low pretax income result write acquire inprocess research development nonrecurre item restate basis effective rate reduce originally report result impact tax matter discuss note restatement previously issue financial statement consolidated financial statement increase effective tax rate benefit operation ireland puerto rico switzerland reflect great percentage total pretax income generate jurisdiction tax rate lower statutory tax rate prepay taxis december million million respectively defer income taxis include asset liability december million million respectively component prepay deferred income taxis consist year end december restate restate dollar million acquire inprocess research development consignment inventory item restructure acquisition divestiture reserve sale return allowance depreciation net increase net prepay defer tax asset million december million december relate primarily acquire process research development consignment inventory item restructure acquisition divestiture reserve charge rise tax deduction future year bristolmyer squibb company note restate consolidated financial statement note income taxis continue income taxis pay year million million million respectively federal income taxis provide substantially unremitte earning nonus subsidiary management practice intent reinvest earning operation subsidiary total net unremitted earning nonus subsidiary approximately billion december certain tax contingency exist probable reasonably estimable amount include taxis payable december certain tax contingency consider probable reasonably estimable company time company reasonably estimate possible contingency possible contingency material effect change estimate related unresolved tax matter include foreignother rate reconciliation company settle federal income tax return internal revenue service subsequent end month end september company recognize income tax benefit million settlement certain tax matter determination company expect settlement ongoing tax litigation exist december current tax benefit realize exercise stock option charge capital excess par amount million million million respectively note account receivable december restate restate dollar million account receivabletrade account receivablemiscellaneous allowance receivables receivables net allowance receivables include allowance bad debt note inventory december restate restate dollar million finished good work process raw packaging material consignment inventory total inventory inventory discontinue operation constitute approximately total company inventory december note property plant equipment december restate restate dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment discontinue operation constitute approximately total company property plant equipment december note shortterm borrowing longterm debt include shortterm borrowing amount bank primarily foreign million million december respectively andcurrent installment longterm debt million december million december weight average interest rate shortterm borrowing current installment longterm debt december respectively company consolidate credit facility aggregate million syndicate lender support commercial paper program new credit facility consist million fiveyear revolve credit facility extendable anniversary date consent lender borrowing outstanding credit facility december addition company unused shortterm line credit foreign bank million component longterm debt december dollar million note note debenture debenture debenture rate yen term loan yen note yen note deutsche mark interest yen principal term loan industrial revenue bond yen term loan variable rate industrial revenue bond capitalize lease vary amount longterm debt december increase million million december largely result financing dupont imclone transaction company issue billion debt note billion mature remain billion mature effective interest rate note respectively effective interest rate issuance approximate state interest rate payment period total dollar millions longterm debt company option redeem time portion note redemption price equal sum principal note redeem plus accrue interest redemption date premium face value pay redeem note result restatement company delay file quarterly report form q quarterly period end september quarter form q previously disclose delay result breach company delivery sec filing obligation indenture indenture company jpmorgan chase bank chase manhattan bank company approximately billion longterm debt outstanding certain credit agreement give certain right trustee indenture respective lender credit agreement accelerate maturity company indebtedness trustee respective lender exercise right accelerate filing quarter form q concurrently file cure noncompliance abovementione obligation indenture credit agreement accordingly debt outstanding indenture credit agreement long accelerate classify current company consolidated balance sheet note stockholder equity change capital share capital excess par value stock share common stock restate capital excess par value issue treasury stock balance december issue pursuant stock plan option conversion prefer stock purchase balance december issue pursuant stock plan option conversion prefer stock purchase balance december issue pursuant stock plan option conversion prefer stock purchase balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share accumulate balance relate component comprehensive income loss follow defer loss accumulate comprehensive foreign currency translation effective hedge loss dollar million balance december adoption sfa comprehensive income loss balance december stock compensation plans company stock incentive plan officer director key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year additionally plan provide grant stock appreciation right grantee surrender exercisable option receive common stock andor cash measure excess market price common stock option exercise price plan provide grant performancebase stock option certain key executive term stock incentive plan amend additional share authorize outstanding share year plan incorporate company longterm performance award addition stock incentive plan provide grant share common stock key employee subject restriction continuous employment case death normal retirement restriction generally expire fiveyear period date grant compensation expense recognize restrict period straightline basis december total restrict share outstanding plan teamshare stock option plan fulltime employee exclude key executive meet certain year service requirement grant option purchase company common stock market price date option grant company authorize share issuance plan individual grant generally exercisable anniversary grant date december share exercise plan company apply accounting principle board opinion accounting stock issue employee relate interpretation accounting plan accordingly compensation expense recognize stockbased compensation plan restrict stock performancebase award compensation cost company stock option plan determine base fair value grant date award plan consistent methodology prescribe sfas accounting stockbase compensation company net income earning share reduce unaudited pro forma basis approximately million common share basic diluted million common share basic diluted million common share basic diluted fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model follow assumption dividend yield volatility riskfree interest rate assume forfeiture rate expect life year stock option transaction wereweighte average share share exercise price share available option plan plan plan balance december authorize grant exercise lapsed balance december authorize grant exercise lapsed balance december authorize grant grant result zimmer spinoff exercise lapse balance december effective spinoff zimmer august unexercised bristolmyers squibb stock option hold zimmer employee convert zimmer stock option remain unexercised bristolmyer squibb stock option number stock option exercise price adjust preserve intrinsic value stock option ratio exercise price fair value exist prior spinoff follow table summarize information concern currently outstanding exercisable option option outstanding option exercisable weighted average weighted average weighted average range exercise remain contractual exercise number exercise price number outstanding life price exercisable price december share common stock reserve issuance pursuant stock plan option conversion prefer stock option relate discontinued operation include amount material bristolmyer squibb company note restate consolidated financial statement note financial instrument company expose market risk change currency exchange rate interest rate result company utilize foreign exchange option forward contract offset effect exchange rate fluctuation anticipate foreign currency transaction primarily intercompany inventory purchase expect occur year company exposure net foreign currency denominate asset liability approximate million million december respectively primarily europe japan mexico canada company mitigate effect exposure thirdparty borrowing exposure net foreign currency denominate asset liability relate discontinued operation include amount material foreign exchange option contract forward contract hedge anticipate transaction company primary foreign currency exposure relation dollar japanese yen euro mexican peso canadian dollar notional amounts company foreign exchange derivative contract december million million respectively derivative qualify hedge future cash flow effective portion change fair value temporarily record comprehensive income recognize earning hedge item affect earning ineffective portion hedge report earning occur notional amount foreign exchange derivative contract relate discontinued operation include amount material manage interest rate risk company utilize interest rate swap contract company enter interest rate swap hedge effect adverse change interest rate future cash outflow interest gain loss change fair value interest rate swap contract designate cash flow hedge initially defer record comprehensive income amount transfer comprehensive income recognize earning interest expense period hedge item recognize earningsin company enter interest rate hedge contract notional billion manage exposure change interest rate longterm fixedrate debt issue connection dupont imclone transaction note acquisition divestiture note alliance investment restate consolidated financial statement contract designate hedge variability cash flow change longterm benchmark interest rate quarter company settle exist interest rate hedge contract coincide issuance long term fixedrate debt company record contract settlement fair value result million defer loss net taxis accumulate comprehensive incomeloss recognize yield adjustment term relate borrowing fair value derivative instrument record prepay expense december million fair value company derivative instrument base relevant market information include current forward currency exchange rate current interest rate fair value option contract estimate blackschole model base yearend currency rate fair value foreign exchange forward contract base yearend forward currency rate carry company financial instrument include cash equivalent marketable security account receivable longterm debt account payable approximate fair value december accordance sfas company record transition adjustment january million net taxis comprehensive incomeloss record derivative instrument fair value reconciliation current period change net taxis include comprehensive incomeloss follow million transition adjustment january net current period decrease fair value net recognize earning net balance december portion end balance include comprehensive income loss expect reclassify earning month approximately million loss note segment information effective quarter company reorganize group support pharmaceutical company relate healthcare business result reorganization company reportable segmentspharmaceutical nutritional healthcare pharmaceutical segment comprise global pharmaceutical international exclude japan consumer medicine business nutritional segment consist mead johnson nutritional primarily infant formula business healthcare segment consist convatec medical imaging consumer medicine japan businesses company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital medical profession wholesaler account approximately net sale restate sale wholesaler account net sale restate sale wholesaler account net sale restate include earning income taxis segment cost capital charge offset cost capital charge include corporateother corporateother include interest expense interest income legal settlement restructuring charge gain sale asset certain administrative expense allocation segment sale select product product category business segment follow year end december restate restate restate dollar million pharmaceutical pravachol glucophage oncology therapeutic network plavix taxol paraplatin zerit avapro monopril serzone buspar nutritional enfamil healthcareostomy earning minority interest income taxis net sale restate restate restate restate restate restate business segment dollar million pharmaceutical nutritional healthcare total segment corporateother net earning minority interest income taxis include earning minority interest income taxis cost capital charge offset cost capital charge include corporateother addition corporateother principally consist interest income interest expense certain administrative expense allocation business segment certain corporate program corporateother include gain sale businessesproduct line million million million respectively provision restructure item million million respectively pharmaceutical segment include charge acquire inprocess research development million million million respectively corporateother asset consist cash cash equivalent time deposit marketable security goodwill certain asset year end asset restate restate dollar million pharmaceutical nutritional healthcare identifiable segment asset corporateother total asset depreciation capital expenditure restate restate restate dollar million pharmaceutical nutritional healthcare business segment total corporateother total capital expenditure depreciation expense consolidate statement cash flow include capital expenditure relate discontinued operation million million million respectively million million million depreciation expense relate discontinued operation respectively geographic area net sale yearend asset restate restate restate restate restate dollar millions united states europe mideast africa western hemisphere pacific total bristolmyer squibb company note restate consolidated financial statement note lease minimum rental commitment noncancelable operating lease primarily real estate effect december dollar million year end december later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million note retirement plan company certain subsidiary define benefit pension plan define contribution plan regular fulltime employee principal pension plan bristolmyers squibb retirement income plan company funding policy contribute amount provide current service fund past service liability plan benefit base primarily year credit service participant compensation plan asset consist principally equity fixedincome securities company domestic curtailmentsettlement loss approximately million result reduction employment level primarily connection restructuring activity clairol divestiture cost company define benefit plan include follow component year end december dollar million service cost benefit earn year interest cost project benefit obligation expect earning plan asset net amortization deferral net pension expense curtailment settlement total pension expense weightedaverage actuarial assumption company pension plan follow december discount rate compensation increase longterm rate return change project benefit obligation plan asset december dollar million benefit obligation begin year service cost benefit earn year interest cost project benefit obligation curtailment settlement transfer dupont actuarial gain loss benefit pay benefit obligation end year fair value plan asset begin year actual earning plan asset employer contribution settlement transfer dupont benefit pay fair value plan asset end year plan asset excess project benefit obligation unamortized net obligation asset adoption unrecognize prior service cost unrecognized net gain loss net recognize amount recognize consolidated balance sheet consist prepay benefit cost accrue benefit liability asset net recognize project benefit obligation accumulate benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset million million million respectively december million million million respectively december million million million respectively december attributable primarily unfunded benefit equalization plan december dupont pharmaceutical company pension plan company recognize minimum pension liability approximately million million december respectively principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million additional information company retirement plan item management discussion analysis financial condition result operation note postretirement benefit plan pension company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity security fixedincome security cost company postretirement benefit plan include follow component year end december dollar million service costbenefit earn year interest cost accumulate postretirement benefit obligation expect earning plan asset net amortization deferral curtailment net postretirement benefit expense weightedaverage actuarial assumption company postretirement benefit plan follow december dollar million discount rate longterm rate return change benefit obligation plan asset year end december dollar million benefit obligation begin year service cost benefit earn year interest cost accumulate postretirement benefit obligation plan participant contribution plan amendment actuarial gain loss curtailment benefit pay benefit obligation end year december dollar million fair value plan asset begin year actual earning plan asset employer contribution plan participant contribution benefit pay fair value plan asset end year accumulate postretirement benefit obligation excess plan asset unrecognize prior service cost unrecognized net gain loss accrue postretirement benefit expense report curtailment relate company restructure divestiture activity measurement purpose annual rate increase capita cost cover health care benefit participant assume rate assume decrease gradually remain level onepercentagepoint change assume health care cost trend rate follow effect percentage percentage point increase point decrease dollar million effect aggregate service interest cost component net postretirement benefit expense effect accumulate postretirement benefit obligation bristolmyer squibb company note restate consolidated financial statement note litigation matter lawsuit claim proceeding pende company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate significant litigation matter describe taxol litigation company file lawsuit assert number generic drug company infringe patent cover method administer paclitaxel file abbreviate new drug application seek regulatory approval sell paclitaxel action consolidate discovery district court district new jersey district court company assert monetary claim defendant seek prevent defendant marketing paclitaxel manner violate patent defendant assert infringe company patent patent invalid unenforceable early district court invalidate claim company patent issue april court appeal federal circuit affirm district court summary judgment invalidity claim patent issue claim relate lowdose threehour administration paclitaxel patient give specify regimen premedicants administration paclitaxel appellate court remand claim district court proceeding company file additional patent infringement suit company seek market generic paclitaxel september defendant receive final approval food drug administration fda abbreviate new drug application paclitaxel marketing product fda announce additional final approval sale additional generic product begin defendant assert counterclaim seek damage allege antitrust unfair competition violation company believe patent valid file suit counterclaim assert believe merit lawsuit defendant assert counterclaim settle defendant agree drop claim relate paclitaxel company grant license certain paclitaxel patent right file initial patent infringement suit private action file party allege antitrust consumer protection similar claim relate company action obtain enforce patent right plaintiff seek declaratory judgment damage include treble andor punitive damage allow disgorgement injunctive relief june group state attorney general district columbia puerto rico virgin islands bring similar claim september federal trade commission ftc initiate investigation relate paclitaxel january company announce reach agreement principle settle substantially antitrust litigation surround taxol taxol antitrust settlement expect million accrue quarter certain important term condition settlement remain finalized certain settlement require court approval final approval state attorney general taxol litigation contingent agreement relate term injunctive relief provision remain negotiate term incorporate certain claimant include number health insurer exist settlement framework company discussion number insurer ultimately join propose settlement predict certainty time company reach agreement ftc staff term consent order resolve ftc investigation propose consent order subject review approval ftc commissioner respect abovementione propose settlement possible time reasonably assess final outcome lawsuit reasonably estimate possible loss range loss respect lawsuit propose settlement final resolve taxolrelate antitrust consumer protection similar claim company prevail final nonappealable determination ensue litigation impact material buspar litigation november company obtain patent patent patent relate method buspar buspirone company timely submit information relate patent fda list fda publication commonly know orange book fda list patent orange book delist patent suit genericdrug manufacturer sue fda company compel delist patent orange book district court decline order delist patent order company cause delist patent orange book company comply court order appeal decision united states court appeal federal circuit appellate court reverse district court order delist concurrently company seek enforce patent action generic drug manufacturer antitrust suit follow delist patent orange book number purchaser buspirone generic drug maker file lawsuit company allege improperly trigger statutory marketing exclusivity plaintiff claim violation antitrust consumer protection similar law attorney general states puerto rico file suit company parallel allegation plaintiff amend allegation include charge agreement company generic company improperly block entry generic buspirone market plaintiff seek declaratory judgment damage include treble andor punitive damage allow disgorgement injunctive relief multidistrict litigation mdl proceedings judicial panel mdl grant company motion patent antitrust case consolidate single forum court buspirone litigation pende issue opinion date february opinion court find patent cover use buspirone infringe second opinion court deny company motion dismiss federal antitrust state law claim second opinion allow claim company proceed federal antitrust claim damagesaccrue year file complaint government investigation ftc number state attorney general initiate investigation concern matter allege antitrust suit discuss company cooperate investigation number attorney general file action company note propose settlement january company announce reach agreement principle settle substantially antitrust litigation surround buspar buspar settlement expect million million accrue fourth quarter million accrue quarter million accrue quarter write settlement agreement number party sign certain settlement require court approval number health insurer agree propose settlement framework case ultimately settle predict certainty time company reach agreement ftc staff term consent order resolve ftc investigation propose consent order subject review approval ftc commissioner respect abovementione propose settlement buspar antitrust litigation possible time reasonably assess final outcome lawsuit reasonably estimate possible loss range loss respect lawsuit propose settlement final resolve busparrelate antitrust consumer protection similar claim company prevail final nonappealable determination ensue litigation impact material vanlev litigation april june company chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd name defendant number class action lawsuit allege violation federal security law regulation action consolidate action district court district new jersey plaintiff claim defendant disseminate materially false misleading statement fail disclose material information concern safety efficacy commercial viability product vanlev period november april plaintiff submit amend complaint add allegation company present chairman board chief executive officer peter r dolan chairman board chief executive officer charle heimbold jr chief scientific officer peter ringrose phd disseminate materially false misleading statement andor fail disclose material information concern safety efficacy commercial viability vanlev period april march number relate class action make essentially allegation file district court southern district new york action transfer district court district new jersey plaintiff purport seek compensatory damage cost expense behalf shareholder possible time reasonably assess final outcome litigation reasonably estimate possible loss range loss respect litigation company prevail final nonappealable determination litigation impact material plavix litigation company owner entity plaintiff pende patent infringement lawsuit united states district court southern district new york entitle sanofisynthelabo sanofi synthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex inc apotex corp cv rws sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v dr reddy laboratories ltd dr reddy laboratories inc cv rws suit base patent disclose claim thing hydrogen sulfate salt clopidogrel market plavix patent disclose claim thing use clopidogrel prevent secondary ischemic event plaintiff infringement position base defendant filing abbreviate new drug application fda seek approval sell generic clopidogrel prior expiration patent suit possible time reasonably assess final outcome lawsuit reasonably estimate possible loss range loss respect lawsuit patent protection plavix lose impact company operation material security matter period march company number current officer name defendant number security class action lawsuit allege violation federal security law regulation plaintiff variously allege defendant disseminate materially false misleading statement fail disclose material information concern different matter safety efficacy commercial viability vanlev discuss company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone system incorporate imclone imclone product erbitux discuss allegation concern vanlev transfer district court district new jersey consolidated action pende remain action consolidate pende district court southern district new york allegation remaining action cover period january april plaintiff seek compensatory damage cost expense october number company officer director director name defendant shareholder derivative suit pende district court southern district new york company nominal defendant suit allege thing violation federal security law breach contract fiduciary duty connection company sale incentive certain wholesaler inventory level wholesaler investment imclone imclone product erbitux similar action pende new york state court plaintiff seek damage cost attorney fee april sec initiate inquiry wholesaler inventory issue reference formal investigation august december investigation expand include certain accounting issue include issue relate establishment reserve account forcertain asset sale october united states attorney office district new jersey announce investigation wholesaler inventory issue reference expand cover subject matter sec investigation company cooperate investigation possible time reasonably assess final outcome litigation investigation reasonably estimate possible loss range loss respect litigation investigation company produce document actively cooperate investigation investigation result assertion criminal andor civil claim company prevail final nonappealable determination litigation investigation impact material erisa litigation december quarter company name defendant number class action bring federal employee retirement income security act erisa case pende district court southern district new york district new jersey plaintiffs allege defendant breach fiduciary duty impose erisa owe participant bristolmyers squibb company saving investment program program include duty disseminate material information concern safety datum company product vanlev company sale incentive certain wholesaler inventory level wholesaler company investment relation imclone imclone product erbitux connection allegation plaintiff assert defendant breach fiduciary duty diversify program asset monitor investment alternative avoid conflict interest remedy allege fiduciary breach cofiduciarie case pende district new jersey plaintiffs additionally allege violation defendant duty disseminate material information concern alleged anticompetitive activity relate company product buspar taxol pravachol plaintiff seek recover loss cause defendant allege violation erisa attorney fee possible time reasonably assess final outcome matter reasonably estimate possible loss range loss respect lawsuit company prevail final nonappealable determination matter impact material average wholesale pricing litigation company number pharmaceutical manufacturer defendant series state federal action private plaintiff bring purport class action complaint file attorney general state county allege manufacturer reporting price certain product result false overstated average wholesale price awp turn improperly inflate reimbursement pay medicare beneficiary insurer state medicaid programs medical plan health care provider prescribe administer product federal case state case include attorney general case remove federal court consolidate pretrial purpose transfer united states district court district massachusetts pharmaceutical industry average wholesale price litigation awp multidistrict litigation september private plaintiff awp multidistrict litigation file master consolidated complaint master complaint supersede complaint preconsolidate constituent case master complaint assert claim federal rico statute state consumer protection fair trade statute company defendant move dismiss master complaint motion hear january nevada montana attorney general move respective case remand state court argument motion schedule march company defendant related state court proceeding new york new jersey california arizona tennessee federal court proceeding new york commence county suffolk new york new jersey state court proceeding currently stay company defendant remove intend remove state court case federal court seek transfer awp multidistrict litigation company anticipate county suffolk case transfer plaintiff seek damage injunctive relief aim manufacturer price reporting practice case preliminary stage company unable assess outcome possible effect business profitability reasonably estimate possible loss range loss respect case company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing marketing practice drug cover medicare andor medicaid requests record come united states attorney office district massachusetts office inspector general department health human service conjunction civil division department justice state company produce document actively cooperate investigation result assertion criminal andor civil claim company unable assess outcome reasonably estimate possible loss range loss respect investigation include imposition fine penalty administrative remedy breast implant litigation company subsidiary medical engineering corporation mec certain company remain defendant number claim lawsuit allege damage personal injury type result polyurethanecovered breast implant smoothwalle breast implant manufacture mec relate company vast majority claim company direct lawsuit resolve settlement trial likewise claim potential claim company register nationwide class action settlement approve federal district court birmingham alabama revise settlement resolve revise settlement company establish accrual respect breast implant product liability litigation company believe possible loss addition amount accrue material note select quarterly financial datum unauditedfor description restatement item effect annual period affect unaudited quarterly datum note restatement previously issue financial statement restate consolidated financial statement quarter second quarter quarter previously previously previously report restate report restate report restate dollar million share datum net sale gross margin net earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning net sale gross margin net earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning fourth quarter year previously previously report restate report restate dollar million share datum net sale gross margin net earning continue operation discontinue operation net net earning earning common sharebasic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning net sale gross margin net earning continue operation discontinue operation net net earning earning common share basic earning continue operation discontinue operation net net earning dilute earning continue operation discontinue operation net net earning fourth quarter include sale dupont million include pretax gain sale businessesproduct line million quarter million second quarter million quarter million fourth quarter quarter quarter fourth quarter include pretax charge acquire inprocess research development million million million respectively second quarter quarter fourth quarter include million reversal prior restructure liability restructure charge million million respectively addition million cost relate dupont acquisition include fourth quarter quarter result include gain sale business million provision restructure item million second quarter result include gain sale business million provision restructure item million quarter result include provision restructure item million fourth quarter result include gain sale business million million taxis quarter result include pretax provision restructure million million taxis quarter result include pretax gain sale business million million taxis pretax provision restructure million million taxis common equivalent share exclude computation dilute loss share fourth quarter effect antidilutive report independent accountant board director stockholder bristolmyers squibb company opinion restate consolidated financial statement list index appear item present fairly material respect restate financial position bristolmyer squibb company subsidiary december result operation cash flow restate year period end december conformity accounting principle generally accept united states america addition opinion restate financial statement schedule list index appear item present fairly material respect information set forth read conjunction relate consolidated financial statement financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free materialmisstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion describe note restatement previously issue financial statement company restate previously issue financial statement describe note accounting policy company change method accounting business combination goodwill transaction consummate subsequent june pricewaterhousecooper llp pricewaterhousecooper llp new york new york march item change disagreement accountant account financial disclosure iv item